Revision as of 13:04, 26 December 2016

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site. Are you looking for a regimen but can't find it here? It is possible that we've moved it to the obsolete regimens page. If you still can't find it, please let us know so we can add it!

81 regimens on this page 131 variants on this page

Untreated, early-stage favorable

Definitions of favorable/unfavorable risk factors vary somewhat across sites; see original sources for details.

ABVD

back to top

ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine

Example orders

Example orders for ABVD in Hodgkin lymphoma

Regimen

Study	Evidence	Comparator	Efficacy
Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)	Phase III	ABVD x 3 -> INRT	Inconclusive whether non-inferior
Radford et al. 2015 (UK NCRI RAPID)	Phase III	ABVD x 3 -> IFRT	Inconclusive whether non-inferior

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycles, see note

Note: Patients in EORTC/LYSA/FIL H10 received 2 cycles of ABVD followed by interim PET-CT; those with a negative interim PET-CT (1 or 2 points on the 5-point Deauville scale) were randomized to receive 2 more cycles of ABVD versus 1 more cycle of ABVD followed by INRT 30 Gy (+ 6 Gy boost); those with a positive PET-CT proceeded to receive escalated BEACOPP followed by INRT 30 Gy (+ 6 Gy boost). Patients in UK NCRI RAPID received 3 cycles of ABVD followed by interim PET-CT; those with a negative PET-CT after the 3rd cycle (1 or 2 points on the 5-point Deauville scale) were randomized to receive IFRT versus no further treatment; those with a positive PET-CT proceeded to receive one more cycle of ABVD followed by IFRT.

References

Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. link to original article contains protocol PubMed
Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. link to original article contains protocol PubMed

ABVD -> RT

back to top

ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine
RT: Radiation Therapy

Example orders

Example orders for ABVD in Hodgkin lymphoma

Regimen #1, ABVD x 2 -> IFRT

Study	Evidence	Comparator	Efficacy
Engert et al. 2010 (GHSG HD10)	Phase III	ABVD x 4 -> IFRT	Seems not superior
Behringer et al. 2014 (GHSG HD13)	Phase III	ABV -> IFRT	Superior FFTF
		AV -> IFRT	Superior FFTF
		AVD -> IFRT	Might have superior FFTF

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 2 cycles, followed by IFRT (see individual protocols for details)

Regimen #2, ABVD x 3 -> IFRT

Study	Evidence	Comparator	Efficacy
Radford et al. 2015 (UK NCRI RAPID)	Phase III	ABVD x 3	Inconclusive whether non-inferior

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 3 cycles, followed by IFRT (see note)

Note: Patients in UK NCRI RAPID received 3 cycles of ABVD followed by interim PET-CT; those with a negative PET-CT after the 3rd cycle (1 or 2 points on the 5-point Deauville scale) were randomized to receive IFRT versus no further treatment; those with a positive PET-CT proceeded to receive one more cycle of ABVD followed by IFRT.

Regimen #3, ABVD x 3 -> INRT

Study	Evidence	Comparator	Efficacy
Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)	Phase III	ABVD x 4	Inconclusive whether non-inferior

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 3 cycles, followed by INRT (see note)

Note: Patients in EORTC/LYSA/FIL H10 received 2 cycles of ABVD followed by interim PET-CT; those with a negative interim PET-CT (1 or 2 points on the 5-point Deauville scale) were randomized to receive 2 more cycles of ABVD versus 1 more cycle of ABVD followed by INRT 30 Gy (+ 6 Gy boost); those with a positive PET-CT proceeded to receive escalated BEACOPP followed by INRT 30 Gy (+ 6 Gy boost).

Regimen #4, ABVD x 4 -> IFRT

Study	Evidence	Comparator	Efficacy
Bonadonna et al. 2004	Phase III	ABVD x 4 -> STNI	Seems not superior
Engert et al. 2010 (GHSG HD10)	Phase III	ABVD x 2 -> IFRT	Seems not superior
Radford et al. 2015 (UK NCRI RAPID)	Non-randomized portion of RCT

Note: Patients in UK NCRI RAPID received 3 cycles of ABVD followed by interim PET-CT; those with a positive PET-CT proceeded to receive a fourth cycle of ABVD followed by IFRT.

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 4 cycles, followed by IFRT (see individual protocols for details)

Regimen #5, ABVD x 2 -> EFRT

Study	Evidence	Comparator	Efficacy
Engert et al. 2007 (GHSG HD7)	Phase III	EFRT	Superior FFTF

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 2 cycles, followed by EFRT (30 Gy + 10 Gy to the involved field)

Regimen #6, ABVD x 4 -> STNI

Study	Evidence	Comparator	Efficacy
Bonadonna et al. 2004	Phase III	ABVD x 4 -> IFRT	Seems not superior

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 4 cycles, followed by STNI

References

Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004 Jul 15;22(14):2835-41. link to original article contains protocol PubMed
Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007 Aug 10;25(23):3495-502. link to original article contains protocol PubMed
Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 Aug 12;363(7):640-52. link to original article PubMed
1. Sub-group analysis: Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.link to original article PubMed
Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. link to original article contains protocol PubMed
Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015 Apr 11;385(9976):1418-27. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396. link to original article PubMed
1. Sub-group analysis: Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.link to original article PubMed
Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. link to original article contains protocol PubMed

AVD -> IFRT

back to top

AVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine
IFRT: Involved Field Radiation Therapy

Regimen

Study	Evidence	Comparator	Efficacy
Behringer et al. 2014 (GHSG HD13)	Phase III	ABV -> IFRT	Not reported
		ABVD -> IFRT	Might have inferior FFTF
		AV -> IFRT	Not reported

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycles

Chemotherapy is followed by IFRT.

References

Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015 Apr 11;385(9976):1418-27. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396. link to original article PubMed
1. Sub-group analysis: Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.link to original article PubMed

MOPP-ABV -> IFRT

back to top

MOPP: Mustargen (Mechlorethamine), Oncovin (Vincristine), Procarbazine, Prednisone
ABV: Adriamycin (Doxorubicin), Bleomycin, Vinblastine
IFRT: Involved Field Radiation Therapy

Regimen

Study	Evidence	Comparator	Efficacy
Fermé et al. 2007 (EORTC-GELA H8-F)	Phase III	Subtotal nodal radiotherapy	Superior OS

Chemotherapy

Mechlorethamine (Mustargen) 6 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose is capped at 2 mg) IV once on day 1
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14
Doxorubicin (Adriamycin) 35 mg/m² IV once on day 8
Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Vinblastine (Velban) 6 mg/m² IV once on day 8

4-week cycle for 3 cycles

Chemotherapy is followed in 3 to 4 weeks by IFRT; see text for details.

References

Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. link to original article contains verified protocol in supplement PubMed

Untreated, early-stage unfavorable

Definitions of favorable/unfavorable risk factors vary somewhat across sites; see original sources for details.

ABVD

back to top

ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine

Example orders

Example orders for ABVD in Hodgkin lymphoma

Regimen

Study	Evidence	Comparator	Efficacy
Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)	Phase III	ABVD x 4 -> INRT	Inconclusive whether non-inferior

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 2 cycles, then:

Patients with a negative interim PET-CT (1 or 2 points on the 5-point Deauville scale) were randomized to receive 4 more cycles of ABVD versus 2 more cycles of ABVD followed by INRT 30 Gy (+ 6 Gy boost). Patients with a positive PET-CT proceeded to receive escalated BEACOPP followed by INRT 30 Gy (+ 6 Gy boost).

References

Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. link to original article contains protocol PubMed

ABVD -> RT

back to top

ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine
RT: Radiation Therapy

Example orders

Example orders for ABVD in Hodgkin lymphoma

Regimen

Study	Evidence	Comparator	Efficacy
Eich et al. 2010 (GHSG HD11)	Phase III	BEACOPP -> IFRT	Seems not superior
von Tresckow et al. 2012 (GHSG HD14)	Phase III	BEACOPPesc x 2 -> ABVD x 2 -> IFRT	Inferior FFTF
Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)	Phase III	ABVD x 6	Inconclusive whether noninferior
Advani et al. 2015 (ECOG E2496)	Phase III	Stanford V -> RT	Seems not superior

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycles, see note

Note: Patients in GHSG HD11 received 4 cycles of ABVD followed by randomization to 20 Gy versus 30 Gy of IFRT. Patients in GHSG HD14 received 4 cycles of ABVD followed by IFRT. Patients in EORTC/LYSA/FIL H10 received 2 cycles of ABVD followed by interim PET-CT; those with a negative interim PET-CT (1 or 2 points on the 5-point Deauville scale) were randomized to receive 4 more cycles of ABVD versus 2 more cycles of ABVD followed by INRT 30 Gy (+ 6 Gy boost); those with a positive PET-CT proceeded to receive escalated BEACOPP followed by INRT 30 Gy (+ 6 Gy boost). Patients in E2496 received 6 to 8 cycles of ABVD; all patients received 36 Gy IFRT to the mediastinum, hila, and supraclavicular regions two to three weeks after completion of chemotherapy.

References

Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27):4199-206. Epub 2010 Aug 16. link to original article contains verified protocol PubMed
von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012 Mar 20;30(9):907-13. Epub 2012 Jan 23. link to original article contains verified protocol PubMed
Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. link to original article contains protocol PubMed
Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42. Epub 2015 Apr 20. link to original article contains limited protocol PubMed

BEACOPP -> IFRT

back to top

BEACOPP: Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone
IFRT: Involved Field Radiation Therapy

Example orders

Example orders for BEACOPP in Hodgkin lymphoma

Regimen

Study	Evidence	Comparator	Efficacy
Eich et al. 2010 (GHSG HD11)	Phase III	ABVD -> IFRT	Seems not superior

Chemotherapy

Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Etoposide (Vepesid) 100 mg/m² IV once per day on days 1 to 3
Doxorubicin (Adriamycin) 25 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 650 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2mg) IV once on day 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14

3-week cycle for 4 cycles

Patients were then randomized to receive 20 Gy versus 30 Gy of IFRT.

References

Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27):4199-206. Epub 2010 Aug 16. link to original article contains verified protocol PubMed

BEACOPP, escalated -> ABVD -> RT

back to top

BEACOPP: Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone
ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine
RT: Radiation Therapy

Regimen

Study	Evidence	Comparator	Efficacy
von Tresckow et al. 2012 (GHSG HD14)	Phase III	ABVD x 4 -> IFRT	Superior FFTF

Chemotherapy, escalated BEACOPP portion

Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Etoposide (Vepesid) 200 mg/m² IV once per day on days 1 to 3
Doxorubicin (Adriamycin) 35 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 1250 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2mg per cycle) IV once on day 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14

Supportive medications

Filgrastim (Neupogen) (dose not specified) SC once per day starting on day 8, continues until ANC > 1000/uL for 3 consecutive days

3-week cycle for 2 cycles, followed by:

Chemotherapy, ABVD portion

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 2 cycles

Treatment was followed by radiation therapy to the involved fields.

References

von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012 Mar 20;30(9):907-13. Epub 2012 Jan 23. link to original article contains verified protocol PubMed

BV + AVD -> ISRT

back to top

BV + AVD: Brentuximab Vedotin, Adriamycin (Doxorubicin), Vinblastine, Dacarbazine
ISRT: Involved Site Radiation Therapy

Regimen

Study	Evidence
Kumar et al. 2016	Phase II

Chemotherapy

Brentuximab vedotin (Adcetris) 1.2 mg/kg IV once per day on days 1 & 15
Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 4 cycles

Chemotherapy is followed by repeat PET-CT; patients with a negative PET-CT proceeded to receive 30 Gy of ISRT.

References

Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11):1458-64. Epub 2016 Jul 25. link to original article contains verified protocol PubMed

MOPP-ABV -> IFRT

back to top

MOPP: Mustargen (Mechlorethamine), Oncovin (Vincristine), Procarbazine, Prednisone
ABV: Adriamycin (Doxorubicin), Bleomycin, Vinblastine
IFRT: Involved Field Radiation Therapy

Regimen #1

Study	Evidence	Comparator	Efficacy
Fermé et al. 2007 (EORTC-GELA H8-U)	Phase III	MOPP-ABV x 6 -> IFRT	Seems not superior
Fermé et al. 2007 (EORTC-GELA H8-U)	Phase III	MOPP-ABV x 4 -> STNI	Seems not superior

Chemotherapy

Mechlorethamine (Mustargen) 6 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose is capped at 2 mg) IV once on day 1
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14
Doxorubicin (Adriamycin) 35 mg/m² IV once on day 8
Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Vinblastine (Velban) 6 mg/m² IV once on day 8

4-week cycle for 4 cycles

Chemotherapy is followed in 3 to 4 weeks by IFRT; see text for details.

Regimen #2

Study	Evidence	Comparator	Efficacy
Fermé et al. 2007 (EORTC-GELA H8-U)	Phase III	MOPP-ABV x 4 -> IFRT	Seems not superior
Fermé et al. 2007 (EORTC-GELA H8-U)	Phase III	MOPP-ABV x 4 -> STNI	Seems not superior

Chemotherapy

Mechlorethamine (Mustargen) 6 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose is capped at 2 mg) IV once on day 1
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14
Doxorubicin (Adriamycin) 35 mg/m² IV once on day 8
Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Vinblastine (Velban) 6 mg/m² IV once on day 8

4-week cycle for 6 cycles

Chemotherapy is followed in 3 to 4 weeks by IFRT; see text for details.

References

Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. link to original article contains verified protocol in supplement PubMed

Stanford V -> RT

back to top

RT: Radiation Therapy

Regimen

Study	Evidence	Comparator	Efficacy
Advani et al. 2015 (E2496)	Phase III	ABVD -> RT	Seems not superior

In Advani et al. 2015 the Stanford V regimen is described as "once per week for 12 weeks." However, the regimen has previously been described as being 4-week cycles for 3 cycles (same duration, but schedule is different). Until this discrepancy is resolved, we replicate the 4-week cycle version here:

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Mechlorethamine (Mustargen) 6 mg/m² IV once on day 1
Etoposide (Vepesid) 60 mg/m² IV once per day on days 15 & 16
Vincristine (Oncovin) 1.4 mg/m² (maximum of 2mg in any individual dose) IV once per day on days 8 & 22
Bleomycin (Blenoxane) 5 units/m² IV once per day on days 8 & 22
Prednisone (Sterapred) 40 mg/m² PO every other day (with taper)

4-week cycle for 3 cycles

All patients received 36 Gy IFRT to the mediastinum, hila, and supraclavicular regions two to three weeks after completion of chemotherapy, with additional IFRT to additional sites ≥ 5 cm (details not described).

References

Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42. Epub 2015 Apr 20. link to original article contains limited protocol PubMed

Untreated, advanced stage

Generally defined as stage III/IV or stage II with bulky disease. Definitions for bulky disease vary across sites; see original sources for details,

ABVD

back to top

ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine

Example orders

Example orders for ABVD in Hodgkin lymphoma

Regimen #1, PET-adapted

Study	Evidence
Zinzani et al. 2016 (HD0801)	Non-randomized
Press et al. 2016 (SWOG S0816)	Phase II
Johnson et al. 2016 (RATHL)	Non-randomized portion of RCT

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 2 cycles, followed by:

HD0801: Patients underwent interim PET-CT after 2 cycles; those with a negative PET-CT by Juweid's criteria received 4 more cycles of ABVD (6 total) and those with initial bulky disease were then randomized to RT versus no further treatment. Those with a positive PET-CT by Juweid's criteria proceeded to salvage IGEV.
SWOG S0816: Patients underwent interim PET-CT after 2 cycles; those with a negative PET-CT by Deauville score (1 to 3) received 4 more cycles of ABVD (6 total); those with a positive PET-CT by Deauville score (4 or 5) proceeded to salvage escalated BEACOPP.
RATHL: Patients underwent interim PET-CT after 2 cycles; those with a negative PET-CT by Deauville score (1 to 3) were randomized to 4 more cycles of ABVD (6 total) versus 4 cycles of AVD; those with a positive PET-CT by Deauville score (4 or 5) proceeded to salvage escalated BEACOPP or salvage BEACOPP-14, specified in advance.

Regimen #2, 8 cycles (ABVD₈)

Study	Evidence	Comparator	Efficacy
Bonadonna et al. 1975	Phase III	MOPP	Seems not superior
Santoro et al. 1987	Phase III	MOPP	Seems to have superior OS
Canellos et al. 1992	Phase III	MOPP	Superior FFS
Canellos et al. 1992	Phase III	MOPP/ABVD	Not reported
Hoskin et al. 2009 (UK NCRI ISRCTN 64141244)	Phase III	Stanford V	Seems not superior
Viviani et al. 2011	Phase III	BEACOPP₄₊₄	Seems to have inferior FFFP
Gordon et al. 2013 (E2496)	Phase III	Stanford V	Seems not superior
Mounier et al. 2014 (LYSA H34)	Phase III	BEACOPP₄₊₄	Might have inferior EFS
Carde et al. 2016 (EORTC 20012)	Phase III	BEACOPP₄₊₄	Seems not superior

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 8 cycles

References

Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975 Jul;36(1):252-9. PubMed
Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987 Jan;5(1):27-37. link to original article PubMed
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84. link to original article PubMed
Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15;21(4):607-14. link to original article PubMed
Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208-18. Epub 2005 Nov 28. link to original article PubMed
Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009 Nov 10;27(32):5390-6. Epub 2009 Sep 8. link to original article PubMed
Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203-12. link to original article contains verified protocol PubMed
Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684-91. Epub 2012 Nov 26. link to original article PubMed
1. Subgroup analysis: Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013 Apr;161(1):76-86. Epub 2013 Jan 29. link to PMC article PubMed
Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). ABVD (8 cycles) versus BEACOPP (4 escalated cycles =4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014 Aug;25(8):1622-8. Epub 2014 May 14. link to original article contains verified protocol PubMed
Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. J Clin Oncol. 2016 Apr 20;34(12):1376-85. Epub 2016 Feb 16. link to original article contains verified protocol PubMed
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016 Jun 10;34(17):2020-7. Epub 2016 Apr 11. link to original article contains verified protocol PubMed
Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36. Epub 2016 Apr 25. link to original article contains verified protocol PubMed
Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. link to original article link to protocol contains verified protocol in supplement PubMed

ABVD, DD-DI

back to top

ABVD, DD-DI: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine, Dose-Dense and Dose-Intense

Regimen

Study	Evidence
Russo et al. 2014	Phase II

Chemotherapy

Doxorubicin (Adriamycin) as follows:
- Cycles 1 to 4: 35 mg/m² IV once per day on days 1 & 11
- Cycles 5 & 6: 25 mg/m² IV once per day on days 1 & 11
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 11
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 11
Dacarbazine (DTIC) 375 mg/m² IV once on days 1 & 11

Supportive medications

Lenograstim (Granocyte) 263 µg SC once per day on days 6 to 8 and days 17 to 19 (6 doses per cycle)

21-day cycle for 6 cycles

References

Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A. A phase II study of dose-dense and dose-intense ABVD (ABVD(DD-DI) ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. Br J Haematol. 2014 Jul;166(1):118-29. Epub 2014 Mar 27. link to original article contains verified protocol PubMed

AVD

back to top

AVD: Adriamycin (Doxorubicin), Vinblastine, Dacarbazine

Regimen

Study	Evidence	Comparator	Efficacy
Johnson et al. 2016 (RATHL)	Phase III	ABVD	Inconclusive whether non-inferior

Treatment preceded by ABVD x 2.

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 4 cycles

References

Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. link to original article link to protocol contains verified protocol in supplement PubMed

BEACOPP

back to top

BEACOPP: Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone

Example orders

Example orders for BEACOPP in Hodgkin lymphoma

Regimen

Study	Evidence	Comparator	Efficacy
Diehl et al. 1997	Non-randomized
Diehl et al. 1998 (GHSG HD9)	Phase III	Escalated dose BEACOPP	Inferior FFTF
Diehl et al. 1998 (GHSG HD9)	Phase III	COPP-ABVD	Seems to have superior OS
Ballova et al. 2005 (GHSG HD9elderly)	Phase III	COPP-ABVD	Seems not superior

Note that this is technically "BEACOPP II." The original "BEACOPP I" is detailed in Diehl et al. 1997 but is of historical interest, only.

Chemotherapy

Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Etoposide (Vepesid) 100 mg/m² IV once per day on days 1 to 3
Doxorubicin (Adriamycin) 25 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 650 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2mg) IV once on day 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14

3-week cycle for 8 cycles

References

Diehl V, Sieber M, Rüffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol. 1997 Feb;8(2):143-8. link to original article contains verified protocol PubMed
Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998 Dec;16(12):3810-21. link to original articlecontains verified protocol PubMed
1. Update: Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003 Jun 12;348(24):2386-95. link to original articlecontains protocol PubMed
2. Update: Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. link to original article PubMed
Ballova V, Rüffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005 Jan;16(1):124-31. link to original articlecontains protocol PubMed

BEACOPP-14

back to top

BEACOPP-14: Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone, 14-day course

Regimen

Study	Evidence	Comparator	Efficacy
Sieber et al. 2003	Phase II
Engert et al. 2012 (GHSG HD15)	Phase III	Escalated BEACOPP x 8	Not reported
Engert et al. 2012 (GHSG HD15)	Phase III	Escalated BEACOPP x 6	Non-inferior FFTF

Chemotherapy

Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Etoposide (Vepesid) 100 mg/m² IV once per day on days 1 to 3
Doxorubicin (Adriamycin) 25 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 650 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2mg) IV once on day 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 80 mg/m² PO once per day on days 1 to 7

Supportive medications

Filgrastim (Neupogen) as follows:
- <75 kg body weight: 300 mcg SC once per day on days 8 to 13
- ≥75 kg body weight: 480 mcg SC once per day on days 8 to 13

2-week cycle for 8 cycles

References

Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003 May 1;21(9):1734-9. link to original article contains verified protocol PubMed
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791-9. Epub 2012 Apr 4. Erratum in: Lancet. 2012 May 12;379(9828):1790. link to original article PubMed

BEACOPP, escalated -> BEACOPP

back to top

BEACOPP: Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone

Regimen

Study	Evidence	Comparator	Efficacy
Viviani et al. 2011	Phase III	ABVD	Seems to have superior FFFP
Borchmann et al. 2011 (GHSG HD12)	Phase III	Escalated BEACOPP	Inferior early progressive disease rate
Mounier et al. 2014 (LYSA H34)	Phase III	ABVD	Might have superior EFS
Carde et al. 2016 (EORTC 20012)	Phase III	ABVD₈	Seems not superior

Frequently referred to as BEACOPP_escalated -> BEACOPP_baseline or BEACOPP₄₊₄.

Escalated portion

Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Etoposide (Vepesid) 200 mg/m² IV once per day on days 1 to 3
Doxorubicin (Adriamycin) 35 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 1250 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2mg per cycle) IV once on day 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14

Supportive medications

Filgrastim (Neupogen) 300 mcg SC once per day starting day 8, continues until ANC > 1000/uL for 3 consecutive days (Viviani et al. 2011) or until day 14 (Mounier et al. 2014)

3-week cycle for 4 cycles, followed by:

Standard portion

Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Etoposide (Vepesid) 100 mg/m² IV once per day on days 1 to 3
Doxorubicin (Adriamycin) 25 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 650 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2mg per cycle) IV once on day 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14

Supportive medications

Filgrastim (Neupogen) 300 mcg SC once per day starting day 8, continues until ANC > 1000/uL for 3 consecutive days (Viviani et al. 2011) or until day 14 (Mounier et al. 2014)

3-week cycle for 4 cycles

References

Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203-12. link to original article contains verified protocol PubMed
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. Epub 2011 Oct 11. link to original article PubMed
Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). ABVD (8 cycles) versus BEACOPP (4 escalated cycles =4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014 Aug;25(8):1622-8. Epub 2014 May 14. link to original article contains verified protocol PubMed
Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36. Epub 2016 Apr 25. link to original article contains verified protocol PubMed

BEACOPP, escalated dose

back to top

BEACOPP: Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone

Example orders

Example orders for escalated dose BEACOPP in Hodgkin lymphoma

Regimen #1

Study	Evidence	Comparator	Efficacy
Engert et al. 2012 (GHSG HD15)	Phase III	BEACOPP-14	Non-inferior FFTF
Engert et al. 2012 (GHSG HD15)	Phase III	Escalated BEACOPP x 8	Seems to have superior OS

Details are not available in the abstract; it is assumed that the regimen is identical to escalated BEACOPP x 8, with 2 fewer cycles.

Chemotherapy

Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Etoposide (Vepesid) 200 mg/m² IV once per day on days 1 to 3
Doxorubicin (Adriamycin) 35 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 1200 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2mg per cycle) IV once on day 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14

3-week cycle for 6 cycles

Regimen #2

Study	Evidence	Comparator	Efficacy
Diehl et al. 1998 (GHSG HD9)	Phase III	BEACOPP	Superior FFTF
Diehl et al. 1998 (GHSG HD9)	Phase III	COPP-ABVD	Seems to have superior OS
Borchmann et al. 2011 (GHSG HD12)	Phase III	Escalated BEACOPP -> BEACOPP	Superior early progressive disease rate
Engert et al. 2012 (GHSG HD15)	Phase III	BEACOPP-14	Not reported
Engert et al. 2012 (GHSG HD15)	Phase III	Escalated BEACOPP x 6	Seems to have inferior OS

Chemotherapy

Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Etoposide (Vepesid) 200 mg/m² IV once per day on days 1 to 3
Doxorubicin (Adriamycin) 35 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 1200 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2mg per cycle) IV once on day 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14

3-week cycle for 8 cycles

References

Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998 Dec;16(12):3810-21. link to original articlecontains verified protocol PubMed
1. Update: Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003 Jun 12;348(24):2386-95. link to original articlecontains protocol PubMed
2. Update: Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. link to original article PubMed
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. Epub 2011 Oct 11. link to original article PubMed
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791-9. Epub 2012 Apr 4. Erratum in: Lancet. 2012 May 12;379(9828):1790. link to original article PubMed

B-AVD; AVD-A

back to top

B-AVD: Brentuximab vedotin, Adriamycin (Doxorubicin), Vinblastine, Dacarbazine
AVD-A: Adriamycin (Doxorubicin), Vinblastine, Dacarbazine, Adcetris (Brentuximab vedotin),

Regimen

Study	Evidence
Younes et al. 2013	Non-randomized

This was a phase I trial but had >20 patients in the MTD expansion cohort; a phase III trial is underway.

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15
Brentuximab vedotin (Adcetris) 1.2 mg/kg IV once per day on days 1 & 15, within "about" 1 hour of AVD infusion completion

4-week cycle for up to 6 cycles

"Consolidative radiotherapy was permitted at the investigator's discretion."

References

Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013 Dec;14(13):1348-56. Epub 2013 Nov 15. link to original article contains verified protocol PubMed
1. Update: Abstract: Joseph M Connors, MD, Stephen Ansell, Steven I. Park, MD, Michelle A. Fanale, M.D. and Anas Younes. Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma: Long Term Outcomes. ASH Annual Meeting 2014, Abstract 292 link to abstract

C-MOPP/ABV

back to top

C-MOPP: CyclophosphaMide, Oncovin (Vincristine), Procarbazine, Prednisone
ABV: Adriamycin (Doxorubicin), Bleomycin, Vinblastine

Regimen

Study	Evidence
Montoto et al. 2000	Phase II

Chemotherapy

Cyclophosphamide (Cytoxan) 650 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum of 3 mg per dose) IV once on day 1
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14
Doxorubicin (Adriamycin) 35 mg/m² IV once on day 8
Bleomycin (Blenoxane) 10 mg/m² IV once on day 8
Vinblastine (Velban) 6 mg/m² IV once on day 8

4-week cycle for 8 cycles

25 to 40 Gy of radiation therapy given over extended fields (mantle or inverted "Y" type) to patients with bulky disease or ones with residual disease after completion of chemotherapy

References

Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer. 2000 May 1;88(9):2142-8. link to original article contains protocol PubMed]

COPP-ABVD, C-MOPP/ABVD

back to top

COPP: Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone
C-MOPP: CyclophosphaMide, Oncovin (Vincristine), Procarbazine, Prednisone
ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine

Regimen

Study	Evidence	Comparator	Efficacy
Diehl et al. 1998 (GHSG HD9)	Phase III	BEACOPP Escalated dose BEACOPP	Seems to have inferior OS
Takenaka et al. 2000 (JCOG 8905)	Phase II
Ballova et al. 2005 (GHSG HD9elderly)	Phase III	BEACOPP	Seems not superior

Chemotherapy, COPP portion

Cyclophosphamide (Cytoxan) 500 mg/m² IV drip once per day on days 1 & 8
Vincristine (Oncovin) 1.4 mg/m² (maximum of 2 mg per dose) IV once per day on days 1 & 8
Procarbazine (Matulane) 100 mg/m² (maximum of 150 mg per dose) PO once per day on days 1 to 14
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 3, 8 to 10

4-week cycle for 5 total cycles of C-MOPP, alternating with 5 total cycles of ABVD

Chemotherapy, ABVD portion

Doxorubicin (Adriamycin) 25 mg/m² IV drip once per day on days 1 & 15
Bleomycin (Blenoxane) 9 mg/m² (maximum of 15 mg per dose) IV drip once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² (maximum of 10 mg per dose) IV once per day on days 1 & 15
Dacarbazine (DTIC) 250 mg/m² IV drip once per day on days 1 & 15

4-week cycle for 5 total cycles of ABVD, alternating with 5 total cycles of C-MOPP

30 Gy of involved field radiation after completion of chemotherapy was given to patients with bulky (=10 cm maximum diameter) disease

Dose modifications

Treatment was postponed for at least 1 week or until recovery if:
- Pretreatment ANC was <1500
- Platelet count was <100 x 10^3
- AST/S-GOT was >100 IU/L
- Total bilirubin was >2
Vincristine (Oncovin) and Vinblastine (Velban) were temporarily discontinued if patients had grade 2 or greater neurotoxicity (e.g. motor weakness, paresthesia, constipation)
Doxorubicin (Adriamycin) was discontinued if cardiac LV ejection fraction was <50%
Bleomycin (Blenoxane) was stopped if the PaO2 was less than 70 mmHg or if it decreased more than 10 mmHg from the previous measurement
Note: Dacarbazine (DTIC) 250 mg/m² was used at this dose reduction based on experiences in a pilot study in which there was severe emesis with Dacarbazine (DTIC) 375 mg/m².

References

Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998 Dec;16(12):3810-21. link to original articlecontains verified protocol PubMed
1. Update: Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003 Jun 12;348(24):2386-95. link to original articlecontains protocol PubMed
Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 2000 Mar;30(3):146-52. link to original article contains protocol PubMed
Ballova V, Rüffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005 Jan;16(1):124-31. link to original articlecontains protocol PubMed

MOPP

back to top

MOPP: Mechlorethamine, Oncovin (Vincristine), Procarbazine, Prednisone

Example orders

Example orders for MOPP in Hodgkin lymphoma

Regimen

Study	Evidence	Comparator	Efficacy
Devita et al. 1970	Phase II
Bonadonna et al. 1975	Phase III	ABVD	Seems not superior
Cooper et al. 1980	Phase III	COPP	Seems not superior
		CVPP	Seems to have inferior CR rate
		MVPP	Seems not superior
Santoro et al. 1982	Phase III	MOPP/ABVD	Inferior PFS
Santoro et al. 1987	Phase III	ABVD	Seems to have inferior OS
Longo et al. 1991	Phase III	MOPP/CABS	Seems not superior
Canellos et al. 1992	Phase III	ABVD	Inferior FFS
Canellos et al. 1992	Phase III	MOPP/ABVD	Seems to have inferior FFS
Somers et al. 1994	Phase III	MOPP/ABVD	Seems to have inferior FFS

Chemotherapy

Mechlorethamine (Mustargen) 6 mg/m² IV once per day on days 1 & 8
Vincristine (Oncovin) 1.4 mg/m² (sometimes each individual dose is capped at 2 mg) IV once per day on days 1 & 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 14
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14

4-week cycle for 6 cycles

References

Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970 Dec;73(6):881-95. link to original article contains protocol PubMed content property of HemOnc.org
Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975 Jul;36(1):252-9. link to original article PubMed
Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. link to original article PubMed
Santoro A, Bonadonna G, Bonfante V, Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med. 1982 Apr 1;306(13):770-5. link to original article PubMed
1. Update: Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med. 1986 Jun;104(6):739-46. link to original article PubMed
Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987 Jan;5(1):27-37. link to original article PubMed
Longo DL, Duffey PL, DeVita VT Jr, Wiernik PH, Hubbard SM, Phares JC, Bastian AW, Jaffe ES, Young RC. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol. 1991 Aug;9(8):1409-20. link to original article PubMed
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84. link to original article PubMed
Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, de Pauw BE, Breed WP, Verdonck L, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol. 1994 Feb;12(2):279-87. link to original article PubMed

MOPP/ABV

back to top

MOPP: Mustargen (Mechlorethamine), Oncovin (Vincristine), Procarbazine, Prednisone
ABV: Adriamycin (Doxorubicin), Bleomycin, Vinblastine

Regimen

Study	Evidence	Comparator	Efficacy
Klimo et al. 1985	Phase II
Glick et al. 1998	Phase III	MOPP -> ABVD	Seems to have superior OS
Duggan et al. 2003	Phase III	ABVD	Seems not superior

Chemotherapy

Mechlorethamine (Mustargen) 6 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose is capped at 2 mg) IV once on day 1
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14
Doxorubicin (Adriamycin) 35 mg/m² IV once on day 8
Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Vinblastine (Velban) 6 mg/m² IV once on day 8

4-week cycle for 6 to 8 cycles

References

Klimo P, Connors JM. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol. 1985 Sep;3(9):1174-82. link to original article contains verified protocol PubMed
Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998 Jan;16(1):19-26. link to original article PubMed
Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15;21(4):607-14. link to original article PubMed

MOPP/ABVD

back to top

MOPP/ABVD: Mustargen (Mechlorethamine), Oncovin (Vincristine), Procarbazine, Prednisone alternating with Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine

Regimen

Study	Evidence	Comparator	Efficacy
Santoro et al. 1982	Phase III	MOPP	Superior PFS
Canellos et al. 1992	Phase III	ABVD	Not reported
Canellos et al. 1992	Phase III	MOPP	Seems to have superior FFS
Somers et al. 1994	Phase III	MOPP	Seems to have superior FFS

To be completed

References

Santoro A, Bonadonna G, Bonfante V, Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med. 1982 Apr 1;306(13):770-5. link to original article PubMed
1. Update: Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med. 1986 Jun;104(6):739-46. link to original article PubMed
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84. link to original article PubMed
Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, de Pauw BE, Breed WP, Verdonck L, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol. 1994 Feb;12(2):279-87. link to original article PubMed
Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol. 1996 May;14(5):1421-30. link to original article PubMed
Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 1997 Apr;15(4):1638-45. Erratum in: J Clin Oncol 1997 Jul;15(7):2762. link to original article PubMed

MOPP/ABVD -> RT

back to top

MOPP: Mustargen (Mechlorethamine), Oncovin (Vincristine), Procarbazine, Prednisone
ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine
RT: Radiation Therapy

Regimen

Study	Evidence
Salvagno et al. 1995	Phase II

To be completed

References

Salvagno L, Sorarù M, Sotti G, Aversa S, Chiarion Sileni V, Mazzarotto R, Scarzello G, Bianco A, Pappagallo GL, Fiorentino MV. Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease. Ann Oncol. 1995 Feb;6(2):173-9. link to original article PubMed
Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Bastian AW, Wilson WH, Wittes RE, Jaffe ES, Hubbard SM, DeVita VT Jr. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. J Clin Oncol. 1997 Nov;15(11):3338-46. link to original article PubMed

PVAG

back to top

PVAG: Prednisone, Vinblastine, Adriamycin (Doxorubicin), Gemcitabine

Regimen

Study	Evidence
Böll et al. 2011	Phase II

This regimen is intended for elderly patients and was also open to patients with early unfavorable disease, but 93% of patients on study had advanced disease.

Chemotherapy

Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 5
Vinblastine (Velban) 6 mg/m² IV once on day 1
Doxorubicin (Adriamycin) 50 mg/m² IV once on day 1
Gemcitabine (Gemzar) 1000 mg/m² IV once on day 1

3-week cycle for 6 to 8 cycles

Patients with PR at the end of treatment underwent 30 Gy of radiotherapy.

References

Böll B, Bredenfeld H, Görgen H, Halbsguth T, Eich HT, Soekler M, Markova J, Keller U, Graeven U, Kremers S, Geissler M, Trenn G, Fuchs M, von Tresckow B, Eichenauer DA, Borchmann P, Engert A. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011 Dec 8;118(24):6292-8. Epub 2011 Sep 13. link to original article contains verified protocol PubMed

Stanford V

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Hoskin et al. 2009 (UK NCRI ISRCTN 64141244)	Phase III	ABVD	Seems not superior
Gordon et al. 2013 (ECOG E2496)	Phase III	ABVD	Seems not superior

Chemotherapy

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Mechlorethamine (Mustargen) 6 mg/m² IV once on day 1
Etoposide (Vepesid) 60 mg/m² IV once per day on days 15 & 16
Vincristine (Oncovin) 1.4 mg/m² (maximum of 2mg in any individual dose) IV once per day on days 8 & 22
Bleomycin (Blenoxane) 5 units/m² IV once per day on days 8 & 22
Prednisone (Sterapred) 40 mg/m² PO every other day (see note below about taper)

Supportive medications

If dose reduction or delay occurred at any time during chemotherapy, Filgrastim (Neupogen) 5 mcg/kg SC once per day x 5 days (starting 48 hours after myelosuppressive chemotherapy) should be given after all subsequent day 1 and 15 doses of chemotherapy. It was not precisely specified when to discontinue Filgrastim (Neupogen).
Ranitidine (Zantac) 150 mg PO BID throughout the course of treatment
Trimethoprim/Sulfamethoxazole (Bactrim DS) (160/800 mg) PO BID throughout the course of treatment
Acyclovir (Zovirax) 200 mg PO TID throughout the course of treatment
Ketoconazole (Nizoral) 200 mg PO once per day throughout the course of treatment; note: this may be optional--Horning SJ et al. J Clin Oncol (2000) listed this as a prophylactic medication, but Horning SJ et al. J Clin Oncol (2002) did not list this when prophylactic medications were specifically listed.

4-week cycle for 3 cycles

36 Gy of consolidative radiation (1.8 Gy in 20 fractions) is started 2 to 4 weeks after chemotherapy is complete and is given to sites of disease ≥ 5 cm and/or to macroscopic nodules in the spleen.

Taper Prednisone (Sterapred) by "10 mg every other day between weeks 10 and 12":
- On week 10, Prednisone (Sterapred) 30 mg/m² PO every other day.
- On week 11, Prednisone (Sterapred) 20 mg/m² PO every other day.
- On week 12, Prednisone (Sterapred) 10 mg/m² PO every other day, then off.
Note: In patients ≥ 50 years old:
- Reduce doses of Vincristine (Oncovin) during cycle 3 to 1 mg.
- Reduce doses of Vinblastine (Velban) during cycle 3 to 4 mg/m².

Dose reductions and delayed treatment:

Doses of Doxorubicin (Adriamycin), Vinblastine (Velban), Mechlorethamine (Mustargen), and Etoposide (Vepesid) were reduced to 65% of the original dose if the ANC on the day of treatment was 500 to 1000. If ANC was <500 the day of treatment, therapy was delayed for 1 week, and therapy resumed the following week at the dose indicated by the ANC. As noted above, Filgrastim (Neupogen) was incorporated into all subsequent treatments if there were any dose reductions or delays.

References

Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol. 1995 May;13(5):1080-8. link to original article PubMed
1. Update: Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002 Feb 1;20(3):630-7. link to original article PubMed
Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol. 2000 Mar;18(5):972-80. link to original article PubMed
Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009 Nov 10;27(32):5390-6. Epub 2009 Sep 8. link to original article PubMed
Edwards-Bennett SM, Jacks LM, Moskowitz CH, Wu EJ, Zhang Z, Noy A, Portlock CS, Straus DJ, Zelenetz AD, Yahalom J. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol. 2010 Mar;21(3):574-81. link to original article PubMed
Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684-91. Epub 2012 Nov 26. link to original article PubMed
1. Subgroup analysis: Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013 Apr;161(1):76-86. Epub 2013 Jan 29. link to PMC article PubMed

VEBEP

back to top

VEBEP: Vepesid (Etoposide), Epirubicin, Bleomycin, Endoxan (Cyclophosphamide), Prednisolone

Regimen

Study	Evidence
Viviani et al. 1999	Phase II

To be completed

References

Viviani S, Bonfante V, Santoro A, Zanini M, Devizzi L, Di Russo AD, Soncini F, Villani F, Ragni G, Valagussa P, Bonadonna G. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am. 1999 Sep-Oct;5(5):275-82. PubMed
Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007 Sep;48(9):1721-7. link to original article PubMed

Untreated

These regimens are not targeted to a particular subgroup of untreated Hodgkin lymphoma.

ABVD

back to top

ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine

Regimen

To be moved to the appropriate indication, see above

Doxorubicin (Adriamycin) 25 mg/m² IV once on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once on days 1 & 15 (1 unit test dose with cycle 1 doses, 60 minutes prior to remainder of full dose)
Vinblastine (Velban) 6 mg/m² IV once on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once on days 1 & 15

4-week cycle for 4 to 6 cycles based on stage, response, and whether radiation therapy is used.

References

Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev. 1982 Mar;9(1):21-35. (no link to original article available) PubMed
Bonadonna G. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1982 Nov;42(11):4309-20. link to original article contains protocol PubMed
Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987 Jan;5(1):27-37. link to original article PubMed
Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJ, Noordijk EM, Tanguy A, Meerwaldt JH, Le Fur R et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993 Nov;11(11):2258-72. link to original article PubMed
Retrospective: Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, Franchi P, Lanic H, Tilly H. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015 Jul;170(2):179-84. Epub 2015 Apr 19. link to original article PubMed

ABVE-PC

back to top

ABVE-PC: Adriamycin (Doxorubicin), Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide

Regimen

Study	Evidence
Schwartz et al. 2009 (COG P9425)	Phase II
Friedman et al. 2014 (AHOD0031)	Non-randomized portion of RCT

This regimen is intended for pediatric patients, younger than 22 years old. Note that first day of chemotherapy is day 0. Bleomycin is referred to as being given at a dose of 5 IU/m² after amendment in P9425 but unclear if this is for cycle 1 only.

Chemotherapy

Doxorubicin (Adriamycin) 30 mg/m² IV once per day on days 0 & 1
Bleomycin (Blenoxane) 10 IU/m² SC/IV once per day on days 0 & 7
Vincristine (Oncovin) 1.4 mg/m² IV once per day on days 0 & 7 (maximum dose per day: 2.8 mg/m²)
Etoposide (Vepesid) 75 mg/m² IV once per day on days 0 to 4
Prednisone (Sterapred) 40 mg/m² PO once per day on days 0 to 7
Cyclophosphamide (Cytoxan) 800 mg/m² IV once on day 0

21-day cycles

References

Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 3;114(10):2051-9. Epub 2009 Jul 7. Erratum: in Blood 2016 128:605 link to original article contains verified protocol PubMed
Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, Kessel S, De Alarcon PA, Chen AR, Kobrinsky N, Ehrlich P, Hutchison RE, Constine LS, Schwartz CL. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014 Nov 10;32(32):3651-8. Epub 2014 Oct 13. link to original article contains protocol PubMed

Brentuximab vedotin (Adcetris)

back to top

Regimen

Study	Evidence
Forero-Torres et al. 2015	Phase II

Chemotherapy

Brentuximab vedotin (Adcetris) as follows:
- eGFR ≥30: 1.8 mg/kg IV once on day 1
  - Dose reduction to 1.2 mg/kg and treatment delay up to 3 weeks allowed for toxicities
- eGFR <30: 1.2 mg/kg IV once on day 1

Supportive medications

"according to institutional standards"

21-day cycle for up to 16 cycles, with continuing treatment allowed for those deriving clinical benefit

References

Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC, Wang Y, Yasenchak CA. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015 Dec 24;126(26):2798-804. Epub 2015 Sep 16. link to original article contains verified protocol PubMed

BV-ABVD

back to top

BV-ABVD: Brentuximab Vedotin, Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine

Regimen

Study	Evidence
Federico et al. 2014	Phase II, <20 patients reported

Brentuximab vedotin portion

Brentuximab vedotin (Adcetris) 1.8 mg/kg IV over 30 minutes

3-week cycle for 2 cycles, followed by:

ABVD portion

Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15 (1 unit test dose with cycle 1 doses, 60 minutes prior to remainder of full dose)
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

4-week cycle for 3 to 6 cycles based on stage, +/- radiation therapy

References

Abstract: Massimo Federico, Emanuela Anna Pesce, Francesco Merli, Stefano Luminari, Stephane Chauvie, Cinzia Pellegrini, Luigi Marcheselli, Isabella Capodanno, Fiorella Ilariucci, Massimiliano Salati, Lisa Argnani, Pier Luigi Zinzani. A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report. J Clin Oncol 32:5s, 2014 (suppl; abstr 8507) link to original abstract

ChlVPP

back to top

ChlVPP: Chllorambucil, Vinblastine, Procarbazine, Prednisone

Regimen

Study	Evidence
International ChIVPP Treatment Group 1995	Phase II

Chemotherapy

Chlorambucil (Leukeran) 6 mg/m² (maximum 10 mg/day) PO once per day on days 1 to 14
Vinblastine (Velban) 6 mg/m² (maximum 10 mg/dose) IV once per day on days 1 & 8
Procarbazine (Matulane) 100 mg/m² (maximum 150 mg/day) PO once per day on days 1 to 14
Prednisone (Sterapred) 40 mg PO once per day on days 1 to 14

4-week cycle to complete remission plus 2 cycles; minimum of 6 cycles and maximum of 8 cycles

References

Retrospective: Druker BJ, Rosenthal DS, Canellos GP. Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease. Cancer. 1989 Mar 15;63(6):1060-4. link to original article PubMed
Selby P, Patel P, Milan S, Meldrum M, Mansi J, Mbidde E, Brada M, Perren T, Forgeson G, Gore M, et al. ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer. 1990 Aug;62(2):279-85. link to PMC article PubMed
The International ChlVPP Treatment Group. ChlVPP therapy for Hodgkin's disease: experience of 960 patients. Ann Oncol. 1995 Feb;6(2):167-72. link to original article contains protocol PubMed

OEPA -> COPDAC

back to top

OEPA: Oncovin (Vincristine), Bleomycin, Prednisone, Adriamycin (Doxorubicin)
COPDAC: Cyclophosphamide, Oncovin (Vincristine), Prednisone, DACarbazine

Regimen

Study	Evidence
Mauz-Körholz et al. 2010 (GPOH-HD-2002)	Phase II

This regimen is meant for boys as it is potentially less gonadotoxic. The original protocol used three doses of dacarbazine per cycle but this was increased to four after a mid-protocol amendment. Patients with early-stage disease only received the OEPA portion, see text for details.

OEPA portion

Vincristine (Oncovin) 1.5 mg/m² IV once per day on days 1, 8, 15
Etoposide (Vepesid) 125 mg/m² IV once per day on days 2 to 6
Prednisone (Sterapred) 60 mg/m² PO once per day on days 1 to 15
Doxorubicin (Adriamycin) 40 mg/m² IV once per day on days 1 & 15

28-day cycle for 2 cycles, followed by:

COPDAC portion

Cyclophosphamide (Cytoxan) 500 mg/m² IV once per day on days 1 & 8
Vincristine (Oncovin) 1.5 mg/m² IV once per day on days 1 & 8
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 15
Dacarbazine (DTIC) 250 mg/m² IV once per day on days 1 to 4

28-day cycle for 2 to 4 cycles, depending on treatment group

References

Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. link to original article contains verified protocol PubMed

OPPA -> COPP

back to top

OPPA: Oncovin (Vincristine), Procarbazine, Prednisone, Adriamycin (Doxorubicin)
COPP: Cyclophosphamide, Oncovin (Vincristine), Prednisone, Procarbazine

Regimen

Study	Evidence
Mauz-Körholz et al. 2010 (GPOH-HD-2002)	Phase II

This regimen is meant for girls. Patients with early-stage disease only received the OEPA portion, see text for details.

OPPA portion

Vincristine (Oncovin) 1.5 mg/m² IV once per day on days 1, 8, 15
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 15
Prednisone (Sterapred) 60 mg/m² PO once per day on days 1 to 15
Doxorubicin (Adriamycin) 40 mg/m² IV once per day on days 1 & 15

28-day cycle for 2 cycles, followed by:

COPP portion

Cyclophosphamide (Cytoxan) 500 mg/m² IV once per day on days 1 & 8
Vincristine (Oncovin) 1.5 mg/m² IV once per day on days 1 & 8
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 15
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 15

28-day cycle for 2 to 4 cycles, depending on treatment group

References

Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. link to original article contains verified protocol PubMed

RABVD

back to top

RABVD: Rituximab, Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine

Regimen #1

Study	Evidence
Younes et al. 2012	Phase II

Chemotherapy

Rituximab (Rituxan) 375 mg/m² IV once per week x 6 weeks
Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

28-day cycle for 6 cycles (except rituximab, which is given for a total of 6 doses)

Regimen #2

Study	Evidence
Kasamon et al. 2012	Phase II

Chemotherapy

Rituximab (Rituxan) as follows:
- Pre-phase: 375 mg/m² IV once one week prior to cycle 1 of ABVD
- Cycle 1: 375 mg/m² IV once per day on days 1, 8, 15, 22
- Cycles 2, 4, 6: 375 mg;m² IV once on day 1
Doxorubicin (Adriamycin) 25 mg/m² IV once per day on days 1 & 15
Bleomycin (Blenoxane) 10 units/m² IV once per day on days 1 & 15
Vinblastine (Velban) 6 mg/m² IV once per day on days 1 & 15
Dacarbazine (DTIC) 375 mg/m² IV once per day on days 1 & 15

28-day cycle for 6 to 8 cycles

References

Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 3;119(18):4123-8. Epub 2012 Feb 27. link to original article contains protocol PubMed
Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 3;119(18):4129-32. Epub 2012 Feb 16. link to original article contains partial protocol PubMed

VEPEMB

back to top

VEPEMB: Vinblastine, Endoxan (Cyclophosphamide), Procarbazine, Etoposide, Mitoxantrone, Bleomycin

Regimen

Study	Evidence	Comparator	Efficacy
Levis et al. 2004	Phase II
Zallio et al. 2016	Phase III	ABVD	Might have inferior PFS

This regimen is intended for elderly patients.

To be completed (?)

References

Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, Gavarotti P, Genua A, Liberati M, Pavone V, Pietrasanta D, Ricetti MM, Scalabrini DR, Salvi F, Vitolo U, Angelucci E, Boccadoro M, Gallo E, Mandelli F; Intergruppo Italiano Linfomi (IIL). VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol. 2004 Jan;15(1):123-8. link to original article PubMed
1. Update: Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, Culligan D, Galloway MJ, Wood KM, McNally RJ, James PW, Goodlad JR. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012 Jun 21;119(25):6005-15. Epub 2012 May 10. link to original article PubMed
Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol. 2016 Mar;172(6):879-88. Epub 2016 Jan 13. link to original article PubMed

Relapsed/refractory

BEACOPP, escalated dose

back to top

BEACOPP: Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone

Regimen #1

Study	Evidence
Johnson et al. 2016 (RATHL)	Non-randomized

Treatment preceded by ABVD x 2, with interim PET-CT showing Deauville score 4 or 5 refractory disease.

Chemotherapy

Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Etoposide (Vepesid) 200 mg/m² IV once per day on days 1 to 3
Doxorubicin (Adriamycin) 35 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 1250 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2mg per cycle) IV once on day 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisolone (Millipred) 40 mg/m² PO once per day on days 1 to 14

Supportive medications

G-CSF 263/300 μg SC once per day on days 9 to 13 OR
Pegfilgrastim (Neulasta) (dose/day not specified) SC once

3-week cycle for 3 to 4 cycles

Regimen #2

Study	Evidence
Press et al. 2016 (SWOG S0816)	Phase II

Treatment preceded by ABVD x 2, with interim PET-CT showing Deauville score 4 or 5 refractory disease.

Chemotherapy

Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Etoposide (Vepesid) 200 mg/m² IV once per day on days 1 to 3
Doxorubicin (Adriamycin) 35 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 1200 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2mg per cycle) IV once on day 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisone (Sterapred) 40 mg/m² PO once per day on days 1 to 14

3-week cycle for 6 cycles

References

Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016 Jun 10;34(17):2020-7. Epub 2016 Apr 11. link to original article refers to original protocol PubMed
Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. link to original article link to protocol contains verified protocol in supplement PubMed

BEACOPP-14

back to top

BEACOPP-14: Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone, 14-day course

Regimen

Study	Evidence
Johnson et al. 2016 (RATHL)	Non-randomized

Treatment preceded by ABVD x 2, with interim PET-CT showing Deauville score 4 or 5 refractory disease.

Chemotherapy

Bleomycin (Blenoxane) 10 units/m² IV once on day 8
Etoposide (Vepesid) 100 mg/m² IV once per day on days 1 to 3
Doxorubicin (Adriamycin) 25 mg/m² IV once on day 1
Cyclophosphamide (Cytoxan) 650 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2mg) IV once on day 8
Procarbazine (Matulane) 100 mg/m² PO once per day on days 1 to 7
Prednisolone (Millipred) 80 mg/m² PO once per day on days 1 to 7

Supportive medications

G-CSF 263/300 μg SC once per day on days 9 to 13 OR
Pegfilgrastim (Neulasta) (dose/day not specified) SC once

2-week cycle for 4 to 6 cycles

References

Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. link to original article link to protocol contains verified protocol in supplement PubMed

BeGEV

back to top

BeGEV: Bendamustine, GEmcitabine, Vinorelbine

Regimen

Study	Evidence
Santoro et al. 2016	Phase II

Chemotherapy

Bendamustine 90 mg/m² IV once per day on days 2 & 3
Gemcitabine (Gemzar) 800 mg/m² IV once per day on days 1 & 4
Vinorelbine (Navelbine) 20 mg/m² IV once on day 1
Prednisolone (Millipred) 100 mg PO once per day on days 1 to 4

Supportive medications

Growth factor support
PJP prophylaxis and antiemetics in accordance with institutional guidelines

21-day cycle for 4 cycles

Patients in who achieved a CR or PR proceeded to BEAM -> autologous hematopoietic cell transplant or FEAM -> autologous hematopoietic cell transplant.

References

Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Salvi F, Merli F, Anastasia A, Luminari S, Annechini G, Gotti M, Peli A, Liberati AM, Di Renzo N, Castagna L, Giordano L, Carlo-Stella C. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. J Clin Oncol. 2016 Sep 20;34(27):3293-9. Epub 2016 Jul 5. link to original article contains verified protocol PubMed

Bendamustine

back to top

Regimen

Study	Evidence
Moskowitz et al. 2013	Phase II

Chemotherapy

Note: these infusion instructions are for the Treanda formulation, which was discontinued on 3/31/2016.

Bendamustine 120 mg/m² IV over 30 minutes once per day on days 1 & 2

Supportive medications

Filgrastim (Neupogen) or Pegfilgrastim (Neulasta) used each cycle; paper does not specify exact timing/duration
PCP prophylaxis and antiemetics according to institutional guidelines

28-day cycle for up to 6 cycles

References

Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ, Graustein T, Zelenetz AD, Moskowitz CH. Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2013 Feb 1;31(4):456-60. Epub 2012 Dec 17. link to original article contains verified protocol PubMed
Retrospective: Anastasia A, Carlo-Stella C, Corradini P, Salvi F, Rusconi C, Pulsoni A, Hohaus S, Pregno P, Viviani S, Brusamolino E, Luminari S, Giordano L, Santoro A. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol. 2014 Jul;166(1):140-2. Epub 2014 Mar 7. link to original article PubMed

Bendamustine & Brentuximab vedotin

back to top

Regimen

Study	Evidence
LaCasce et al. 2014	Phase II

Chemotherapy

Bendamustine 90 mg/m² IV once per day on days 1 & 2
Brentuximab vedotin (Adcetris) 1.8 mg/kg IV once on day 1

21-day cycle for up to 6 cycles

References

Abstract: LaCasce A, Bociek RG, Matous J, et al. Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy. Presented at: 2014 ASH Annual Meeting; December 6-9, 2014; San Francisco, CA. Abstract 293 link to abstract.

Brentuximab vedotin (Adcetris)

back to top

Regimen #1

Study	Evidence
Younes et al. 2012 (SG035-0003)	Phase II
Gopal et al. 2012	Non-randomized
Bartlett et al. 2014	Phase II

Note: Bartlett et al. 2014 is a re-treatment trial; all patients were previously exposed to brentuximab vedotin. Patients who had received the 1.2 mg/kg dose on a prior trial also received that dose at re-treatment.

Chemotherapy

Brentuximab vedotin (Adcetris) 1.8 mg/kg IV over 30 minutes once on day 1

Supportive medications

Rothe et al. 2012: "no premedications were administered"

21-day cycles, given until progression or up to 16 infusions (SG035-0003)

Regimen #2

Study	Evidence
Moskowitz et al. 2015	Phase II

Chemotherapy

Brentuximab vedotin (Adcetris) 1.2 mg/kg IV once per day on days 1, 8, 15

28-day cycle for 2 cycles

PET-negative patients (a Deauville score of 1 or 2) proceeded to autologous hematopoietic cell transplant with BEAM, CBV, or high dose chemoradiotherapy. All others proceeded to receive two cycles of augmented ICE prior to transplant.

References

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012 Jun 20;30(18):2183-9. Epub 2012 Mar 26. link to original article contains verified protocol PubMed
1. Update: Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Chi X, Sievers EL, Younes A. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015 Feb 19;125(8):1236-43. Epub 2014 Dec 22. link to original article PubMed
2. Update: Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016 Sep 22;128(12):1562-6. Epub 2016 Jul 18. link to original article PubMed
Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, Zain J. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012 Jul 19;120(3):560-8. Epub 2012 Apr 17. link to original article contains verified protocol PubMed
Retrospective: Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jäger U, Bangard C, Böll B, von Bergwelt Baildon M, Theurich S, Borchmann P, Engert A. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012 Aug 16;120(7):1470-2. Epub 2012 Jul 11. link to original article contains verified protocol PubMed
Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013 Apr;98(4):611-4. Epub 2012 Oct 12. link to original article contains verified protocol PubMed
Retrospective: Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014 Oct;55(10):2328-34. Epub 2014 Feb 24. link to original article PubMed
Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014 Mar 19;7:24. link to original article contains verified protocol PubMed
Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar;16(3):284-92. Epub 2015 Feb 13. link to original article contains protocol PubMed
Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-40. Epub 2015 Jul 26. link to original article PubMed

DHAP

back to top

DHAP: Dexamethasone, High-dose Ara-C (Cytarabine), Platinol (Cisplatin)

Regimen

Study	Evidence
Valesquez et al. 1988	Phase II
Sureda et al. 2011	Phase II

Chemotherapy

Dexamethasone 40 mg PO/IV over 15 minutes once per day on days 1 to 4
Cytarabine (Cytosar) as follows:
- 70 and younger: 2000 mg/m² IV given over 3 hours Q12H x 2 doses on day 2
- >70 years old: 1000 mg/m² IV given over 3 hours Q12H x 2 doses on day 2
Cisplatin (Platinol) 100 mg/m² IV continuous infusion over 24 hours on day 1

Supportive medications

Normal saline with mannitol 50 g/L given at 250 mL/H x 36 hours, starting 6 hours before Cisplatin (Platinol) infusion was started

21 to 28-day cycles (depending on degree of myelosuppression)

Velasquez et al. 1988 gave 6 to 10 cycles, with therapy given 4 cycles beyond the maximum antitumor effect. Sureda et al. 2011 gave 2 cycles, with responders proceeding to RIC allogeneic hematopoietic cell transplant.

Aside from the table below (from Velasquez et al. 1988), there were no specific cutoff criteria about dose modifications or delays of treatment.

Dose modifications
Event	Cytarabine (Cytosar)	Cisplatin (Platinol)
ANC <200	1000 mg/m² x 2 doses	100 mg/m²
Platelets <20 x 10^3	1000 mg/m² x 2 doses	100 mg/m²
Sepsis associated with neutropenia	500 mg/m² x 1 dose	100 mg/m²
Cr 1.5 to 2.0	-	75 mg/m²
Cr 2.1-3.0	-	50 mg/m²

References

Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, Barlogie B. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan;71(1):117-22. link to original article contains protocol PubMed
Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ, García-Noblejas A, López Corral L, Xicoy B, Sierra J, Schmitz N. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012 Feb;97(2):310-7. Epub 2011 Oct 11. link to original article contains protocol PubMed

DHAP - time intensified

back to top

DHAP: Dexamethasone, High-dose Ara-C (Cytarabine), Platinol (Cisplatin)

Regimen

Study	Evidence
Josting et al. 2002	Phase II

This was used as a salvage regimen for relapsed/refractory Hodgkin Lymphoma in patients who were planned for high-dose chemotherapy (HDCT) and autologous hematopoietic cell transplantation.

Chemotherapy

Dexamethasone 40 mg IV once per day on days 1 to 4
Cytarabine (Cytosar) 2000 mg/m² IV given over 3 hours Q12H x 2 doses on day 2
Cisplatin (Platinol) 100 mg/m² IV continuous infusion over 24 hours on day 1

Supportive medications

Hydration at 250 mL/H started 2 to 6 hours before Cisplatin (Platinol) infusion was started
Prednisolone acetate 1% eyedrops 1 drop to both eyes TID; start 12 hours before start of Cytarabine (Cytosar) and continued for 2 days after cytarabine administration complete
Ondansetron (Zofran) 8 mg IV once per day on days 1 & 2
Filgrastim (Neupogen) 5 mcg/kg SQ per day, start 24 hours after last dose of Cytarabine (Cytosar) and continue until ANC >2,500 for 3 days

Variable number of days between cycles depending on count recovery x 2 cycles Median time between cycle 1 and 2 was 16 days. The paper did not definitively specify what criteria needed to be fulfilled before cycle 2 was given. Baseline eligibility criteria for the study included WBC >3.5 x 10^3, Hb =8, platelets =100 x 10^3.

References

Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A; Participating Centers. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002 Oct;13(10):1628-35. link to original article contains protocol PubMed

ESHAP

back to top

ESHAP: Etoposide, Solumedrol (Methylprednisolone) High-dose Ara-C (Cytarabine), Platinol (Cisplatin)

Regimen

Study	Evidence
Aparicio et al. 1999	Phase II

Note that the authors state that they used the protocol defined by Velasquez et al. 1994. However, there are some differences in the text describing methylprednisolone dosing from that in the original article. Below are the doses reported in the original article, with the addition of G-CSF as specified in Aparicio et al. 1999.

Chemotherapy

Etoposide (Vepesid) 40 mg/m² IV over 1 hour once per day on days 1 to 4
Methylprednisolone (Solumedrol) 250 to 500 mg IV over 15 minutes once per day on days 1 to 5
Cytarabine (Cytosar) 2000 mg/m² IV over 2 hours once on day 5
Cisplatin (Platinol) 25 mg/m²/day IV continuous infusion on days 1 to 4 (total dose per cycle: 100 mg/m²)

Supportive medications

At least 1 liter normal saline with 25 to 50 g Mannitol once per day throughout chemotherapy
Metoclopramide (Reglan) 0.5 to 1 mg/kg "given regularly"
Filgrastim (Neupogen) 5 mcg/kg SC once per day on days 6 to 18

21- to 28-day cycle for 3 cycles; see below

Transplant eligible patients with "responsive disease" after 3 cycles proceeded to receive CBV followed by autologous transplant. Transplant ineligible patients with "responsive disease" received 3 more cycles of ESHAP (6 total).

References

Aparicio J, Segura A, Garcerá S, Oltra A, Santaballa A, Yuste A, Pastor M. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol. 1999 May;10(5):593-5. link to original article contains verified protocol PubMed

Everolimus (Afinitor)

back to top

Regimen

Study	Evidence
Johnston et al. 2010	Phase II

Chemotherapy

Everolimus (Afinitor) 10 mg PO once per day on an empty stomach

Supportive medications

"Patients could receive white blood cell growth factors if neutropenia developed. Erythropoietin treatment for anemia was permitted."

28-day cycles, given until progression or unacceptable toxicity

References

Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May;85(5):320-4. link to original article contains verified protocol PubMed

GCD +/- R

back to top

GCD +/- R: Gemcitabine, Carboplatin, Dexamethasone, Rituximab

Regimen

Study	Evidence
Gopal et al. 2010	Phase II

Chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1 & 8
Carboplatin (Paraplatin) AUC 5 IV over 30 minutes once on day 1
Dexamethasone 40 mg PO once per day on days 1 to 4
If disease is CD20 positive: Rituximab (Rituxan) 375 mg/m² slow IV infusion once on day 8

Supportive medications

Growth factor support and antibiotic prophylaxis used is at the discretion of the treating physician.

3-week cycle for up to 4 cycles

Dose modifications:

If on day 8, platelets are 50 to 100 or ANC 500 to 1000: reduce Gemcitabine (Gemzar) dose by 25% for that dose only.
If on day 8, platelets are <50 or ANC <500: No day 8 Gemcitabine (Gemzar) dose given.
Subsequent cycles would be given at full dose if patients had platelets <50 or ANC <1000.
If counts were not adequate, the next cycle can be delayed for up to 3 weeks until counts are adequate for treatment.

References

Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT, Garrison MA, Gjerset GF, Lonergan M, Murphy AE, Smith JC, Pagel JM. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma. 2010 Aug;51(8):1523-9. link to PMC article contains protocol PubMed

Gemcitabine (Gemzar)

back to top

Regimen

Study	Evidence
Santoro et al. 2000	Phase II

Chemotherapy

Gemcitabine (Gemzar) as follows:
- Cycle 1: 1250 mg/m² IV over 30 minutes once per day on days 1, 8, 15
- Subsequent cycles (if no hematologic or nonhematologic toxicities): 1500 mg/m² IV over 30 minutes once per day on days 1, 8, 15

4-week cycles until progression or intolerance

References

Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000 Jul;18(13):2615-9. link to original article contains verified protocol PubMed

Gemcitabine & Rituximab

back to top

Regimen

Study	Evidence
Oki et al. 2007	Phase II

Patients had received at least 2 prior chemotherapy regimens.

Chemotherapy

Gemcitabine (Gemzar) 1250 mg/m² IV over 30 minutes once per day on days 1 & 8
Rituximab (Rituxan) 375 mg/m² IV once per week for the first 2 cycles (6 doses total)

21-day cycle for up to 6 cycles

Dose modifications:

Gemcitabine (Gemzar)

Dose level 0: 1250 mg/m²
Dose level -1: 1000 mg/m²
Dose level -2: 750 mg/m²
If ANC ≤1000 on day 1 of the following cycle, delay until count recovery
If ANC remains ≤1000 for one week or longer, reduce dose by one level
If platelets ≤50,000 on day 1 of the following cycle, delay until count recovery AND reduce dose by one level

References

Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008 Feb 15;112(4):831-6. link to original article contains verified protocol PubMed

GVD

back to top

GVD: Gemcitabine, Vinorelbine, Doxil (Liposomal doxorubicin)

Regimen

Study	Evidence
Bartlett et al. 2007 (CALGB 59804)	Phase II

Transplant-naive patients

Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1 & 8 second medication given
Vinorelbine (Navelbine) 20 mg/m² IV over 6 to 10 minutes once per day on days 1 & 8 first medication given
Doxorubicin liposomal (Doxil) 15 mg/m² IV over 30 to 60 minutes once per day on days 1 & 8 third medication given

3-week cycle for 2 to 6 cycles

Post-transplant patients

Gemcitabine (Gemzar) 800 mg/m² IV over 30 minutes once per day on days 1 & 8 second medication given
Vinorelbine (Navelbine) 15 mg/m² IV over 6 to 10 minutes once per day on days 1 & 8 first medication given
Doxorubicin liposomal (Doxil) 10 mg/m² IV over 30 to 60 minutes once per day on days 1 & 8 third medication given

3-week cycle for 2 to 6 cycles

Dose levels: Note: These dose levels are listed primarily for historical purposes and were used in the trial while dose levels and dose limiting toxicities (DLT) and maximum tolerated dose (MTD) were being determined. The MTD dosages used above correspond to dose level 1 for transplant-naive patients and dose level -1 for post-transplant patients.

Dose level 1:
- Vinorelbine (Navelbine) 20 mg/m² IV over 6 to 10 minutes once per day on days 1 & 8
- Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1 & 8
- Doxorubicin liposomal (Doxil) 15 mg/m² IV over 30 to 60 minutes once per day on days 1 & 8
Dose level 2:
- Vinorelbine (Navelbine) 20 mg/m² IV over 6 to 10 minutes once per day on days 1 & 8
- Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1 & 8
- Doxorubicin liposomal (Doxil) 20 mg/m² IV over 30 to 60 minutes once per day on days 1 & 8
Dose level -1:
- Vinorelbine (Navelbine) 15 mg/m² IV over 6 to 10 minutes once per day on days 1 & 8
- Gemcitabine (Gemzar) 800 mg/m² IV over 30 minutes once per day on days 1 & 8
- Doxorubicin liposomal (Doxil) 10 mg/m² IV over 30 to 60 minutes once per day on days 1 & 8

Dose modifications

If febrile neutropenia occurs: Decrease treatment by one dose level.
If febrile neutropenia occurs on dose level -1: treating physician can choose to either:
1. Use Filgrastim (Neupogen) or Sargramostim (Leukine).
2. Reduce dose of Gemcitabine (Gemzar) and Vinorelbine (Navelbine) by 25% for all subsequent cycles.
If febrile neutropenia reoccurred despite dose reduction patient were discontinued from this protocol.

If on day 8, platelets are 50 to 100 or ANC 500 to 1000: reduce Gemcitabine (Gemzar) dose by 25% for that dose only.
If on day 8, platelets are <50 or ANC <500: No day 8 Gemcitabine (Gemzar) dose given.
Subsequent cycles would be given at full dose if patients had platelets =50 or ANC =1000.
If counts were not adequate, the next cycle can be delayed for up to 3 weeks until counts are adequate for treatment.

References

Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP; Cancer Leukemia Group B. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007 Jun;18(6):1071-9. link to original article contains protocol PubMed

GVP

back to top

GVP: Gemcitabine, Vinorelbine, Prednisolone

Regimen

Study	Evidence
Naqi et al. 2013	Phase II

Chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV once per day on days 1 & 8
Vinorelbine (Navelbine) 30 mg/m² IV over 6 to 10 minutes once per day on days 1 & 8
Prednisolone (Millipred) 100 mg PO once per day on days 1 to 5

28-day cycle for 4 cycles

References

Naqi N, Ahmad S, Shah I, Khattak J. A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma. J Coll Physicians Surg Pak. 2013 Jun;23(6):397-400. PubMed

ICE

back to top

ICE: Ifosfamide, Carboplatin, Etoposide

Regimen #1

Study	Evidence
Moskowitz et al. 2001	Phase II

Chemotherapy

Ifosfamide (Ifex) 5000 mg/m² IV continuous infusion over 24 hours on day 2; mixed in same solution as Mesna (Mesnex)
Carboplatin (Paraplatin) AUC 5 (maximum dose of 800 mg) IV once on day 2
Etoposide (Vepesid) 100 mg/m² IV once per day on days 1 to 3

Supportive medications

Mesna (Mesnex) 5000 mg/m² IV continuous infusion over 24 hours on day 2; mixed in same solution as Ifosfamide (Ifex)
Filgrastim (Neupogen) 5 mcg/kg SC once per day on days 5 to 12
No dose reductions--treatment is delayed until ANC is >1000 and platelets >50 x 10^3

2-week cycle for 2 cycles

Regimen #2, "Augmented ICE"

Study	Evidence
Moskowitz et al. 2015	Phase II

Treatment preceded by brentuximab vedotin.

Chemotherapy

Ifosfamide (Ifex) 5000 mg/m²/day IV continuous infusion over 48 hours on days 1 & 2 (total dose = 10,000 mg/m²); mixed in same solution as Mesna (Mesnex)
Carboplatin (Paraplatin) AUC 5 IV once on day 3
Etoposide (Vepesid) 200 mg/m² IV q12h on day 1 (3 doses total)

Supportive medications

Mesna (Mesnex) 5000 mg/m²/day IV continuous infusion over 48 hours on days 1 & 2; mixed in same solution as Ifosfamide (Ifex)

2 cycles

Autologous hematopoietic cell transplant was "considered" after 2 cycles; criteria not listed in the abstract.

References

Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O'Brien JP, Straus D, Portlock CS, Yahalom J. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001 Feb 1;97(3):616-23. link to original article contains protocol PubMed
Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar;16(3):284-92. Epub 2015 Feb 13. link to original article contains protocol PubMed

Ifosfamide & Vinorelbine

back to top

Regimen

Study	Evidence
Bonfante et al. 1998	Phase II

Chemotherapy

Ifosfamide (Ifex) 3000 mg/m²/day IV continuous infusion on days 1 to 4 (total dose = 12,000 mg/m²)
Vinorelbine (Navelbine) 25 mg/m² IV once per day on days 1 & 5

Supportive medications

Mesna (Mesnex) 3000 mg/m²/day IV admixed with Ifosfamide (Ifex)
Prednisone (Sterapred) 50 mg IV once per day on days 1 to 5
Filgrastim (Neupogen) 5 mcg/kg SC once per day on days 7 to 14

3-week cycles

References

Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M, Soncini F, Soto Parra H, Valagussa P, Bonadonna G. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol. 1998 Nov;103(2):533-5. link to original article contains verified protocol PubMed
Bonfante V, Viviani S, Devizzi L, Di Russo A, Di Nicola M, Magni M, Matteucci P, Grisanti S, Valagussa P, Bonadonna G, Gianni AM. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Eur J Haematol Suppl. 2001 Jul;64:51-5. contains protocol PubMed

IGEV

back to top

IGEV: Ifosfamide, GEmcitabine, Vinorelbine

Regimen

Study	Evidence
Santoro et al. 2007	Phase II
Zinzani et al. 2016 (HD0801)	Non-randomized

Treatment in HD0801 was preceded by ABVD x 2.

Chemotherapy

Ifosfamide (Ifex) 2000 mg/m² IV over 2 hours once per day on days 1 to 4
Gemcitabine (Gemzar) 800 mg/m² IV once per day on days 1 & 4
Vinorelbine (Navelbine) 20 mg/m² IV once on day 1
Prednisolone (Millipred) 100 mg PO once per day on days 1 to 4

Supportive medications

2L saline solution hyperhydration days 1 to 4
Mesna (Mesnex) 2600 mg/m² IV once per day on days 1 to 4
Filgrastim (Neupogen) (dose not specified, but could assume 5 mcg/kg) SC once per day on days 7 to 12, or up to apheresis in the course of hematopoietic cell mobilization

21-day cycle for 4 cycles

Patients in HD0801 who achieved a CR proceeded to BEAM -> autologous hematopoietic cell transplant.

References

Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica. 2007 Jan;92(1):35-41. link to original article contains verified protocol PubMed
Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. J Clin Oncol. 2016 Apr 20;34(12):1376-85. Epub 2016 Feb 16. link to original article refers to Santoro et al. 2007 PubMed

Lenalidomide (Revlimid)

back to top

Regimen

Study	Evidence
Fehniger et al. 2011	Phase II

Chemotherapy

Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21

Supportive medications

Aspirin (81 or 325 mg) PO once per day as prophylactic anticoagulation; those "deemed to be at high risk of deep venous thrombosis by the treating physician" were given Warfarin (Coumadin) or low-molecular-weight heparin.

28-day cycles

References

Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011 Nov 10;118(19):5119-25. Epub 2011 Sep 21. link to original article link to PMC article contains verified protocol PubMed

MINE

back to top

MINE: Mesna, Ifosfamide, Novantrone (Mitoxantrone), Etoposide

Regimen

Study	Evidence
Rodriguez et al. 1995	Phase II

Chemotherapy

Mesna (Mesnex) 1.33 g/m² IV over 1 hour once per day on days 1 to 3; mixed in same solution as Ifosfamide (Ifex)
- Mesna (Mesnex) 500 mg PO 4 hours after each IV dose of Ifosfamide (Ifex) once per day on days 1 to 3
Ifosfamide (Ifex) 1.33 g/m² IV over 1 hour once per day on days 1 to 3; mixed in same solution as Mesna (Mesnex)
Mitoxantrone (Novantrone) 8 mg/m² IV once on day 1
Etoposide (Vepesid) 65 mg/m² IV over 1 hour once per day on days 1 to 3

3 to 4-week cycle for up to 6 cycles in responding patients

References

Rodriguez MA, Cabanillas FC, Hagemeister FB, McLaughlin P, Romaguera JE, Swan F, Velasquez W. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995 Jul;6(6):609-11. link to original article contains protocol PubMed

Mini-BEAM

back to top

BEAM: BiCNU (Carmustine), Etoposide, Ara-C (Cytarabine), Melphalan

Regimen #1

Study	Evidence
Fernández-Jiménez et al. 1999	Phase II

Chemotherapy

Carmustine (BiCNU) 60 mg/m² IV once on day 1
Etoposide (Vepesid) 300 mg/m² IV once on day 1
Cytarabine (Cytosar) 800 mg/m² IV once on day 1
Melphalan (Alkeran) 30 mg/m² IV once on day 1

4-week cycle for 2 to 3 cycles

Regimen #2

Study	Evidence
Colwill et al. 1995	Phase II

Chemotherapy

Carmustine (BiCNU) 60 mg/m² IV over 30 minutes once on day 1
Etoposide (Vepesid) 75 mg/m² IV over 30 minutes once per day on days 2 to 5
Cytarabine (Cytosar) 100 mg/m² IV Q12H on days 2 to 5
Melphalan (Alkeran) 30 mg/m² IV over 15 minutes once on day 6

Supportive medications

If febrile neutropenia occurred during previous cycle: Ciprofloxacin (Cipro) 500 mg PO once per day
Patients were transfused to keep Hb ≥8, platelets ≥20
There was no routine use of G-CSF or GM-CSF

4 to 6 week cycles, depending on hematologic recovery

Patients eligible for autologous hematopoietic cell transplant received no more than 2 cycles; otherwise total # of cycles not reported

References

Colwill R, Crump M, Couture F, Danish R, Stewart AK, Sutton DM, Scott JG, Sutcliffe SB, Brandwein JM, Keating A. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995 Feb;13(2):396-402. link to original article contains protocol PubMed
Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. Haematologica. 1999 Nov;84(11):1007-11. link to original article contains verified protocol PubMed
1. Update: Martín A, Fernández-Jiménez MC, Caballero MD, Canales MA, Pérez-Simón JA, García de Bustos J, Vázquez L, Hernández-Navarro F, San Miguel JF. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol. 2001 Apr;113(1):161-71. link to original article contains protocol PubMed

Nivolumab (Opdivo)

back to top

Regimen #1, every 2 weeks

Study	Evidence
Younes et al. 2016	Phase II

Immunotherapy

Nivolumab (Opdivo) 3 mg/kg IV every 2 weeks

Continued until disease progression or treatment intolerance

Regimen #2, with lead-in

Study	Evidence
Ansell et al. 2014	Non-randomized

Immunotherapy

Nivolumab (Opdivo) 3 mg/kg IV once per week on week 1, week 4, and then every 2 weeks

Continued until disease progression, or complete response, or up to 2 years

References

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med. 2015 Jan 22;372(4):311-9. Epub 2014 Dec 6. link to original article contains verified protocol PubMed
Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1283-94. Epub 2016 Jul 20. link to original article contains protocol PubMed

O-ESHAP

back to top

O-ESHAP: Ofatumumab, Etoposide, Solumedrol (Methylprednisolone) High-dose Ara-C (Cytarabine), Platinol (Cisplatin)

Regimen

Study	Evidence
Martínez et al. 2016 (GELTAMO)	Phase II

Note that the ofatumumab dosing is described in the abstract but the ESHAP is not. The ESHAP doses here are from the protocol defined by Velasquez et al. 1994.

Chemotherapy

Ofatumumab (Arzerra) as follows:
- Cycle 1: 1000 mg IV once per day on days 1 & 8
- Cycles 2 & 3: 1000 mg IV once on day 1
Etoposide (Vepesid) 40 mg/m² IV over 1 hour once per day on days 1 to 4
Methylprednisolone (Solumedrol) 250 to 500 mg IV over 15 minutes once per day on days 1 to 5
Cytarabine (Cytosar) 2000 mg/m² IV over 2 hours once on day 5
Cisplatin (Platinol) 25 mg/m²/day IV continuous infusion on days 1 to 4 (total dose per cycle: 100 mg/m²)

Number of cycles not specified

References

Martínez C, Díaz-López A, Rodriguez-Calvillo M, García-Sanz R, Terol MJ, Pérez-Ceballos E, Jiménez MJ, Cantalapiedra A, Domingo-Domenech E, Rodriguez MJ, Sampol A, Espeso M, López FJ, Briones J, García JF, Sureda A; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO). Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol. 2016 Sep;174(6):859-67. 2016 May 17. link to original article contains protocol PubMed

Panobinostat (Farydak)

back to top

Regimen

Study	Evidence	ORR	Pt Population
Younes et al. 2012	Phase II	Investigator assessment: 27% Central review: 22%	Progressed after autoHCT and had a median of 4 prior systemic regimens (range 2 to 7)

Chemotherapy

Panobinostat (Farydak) 40 mg PO three times per week (e.g., MWF)

21-day cycles until progression or intolerance

References

Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, Harrison SJ, Kirschbaum M, Johnston P, Gallagher J, Le Corre C, Shen A, Engert A. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012 Jun 20;30(18):2197-203. Epub 2012 Apr 30. link to original article contains verified protocol PubMed

Rituximab (Rituxan)

back to top

Regimen

Study	Evidence
Younes et al. 2003	Pilot, >20 pts

Patients had received a minimum of 2 prior systemic regimens. All reported patients had nodular sclerosis histology.

Chemotherapy

Rituximab (Rituxan) 375 mg/m² IV once per week

6-week course (6 doses total)

References

Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003 Jul 15;98(2):310-4. link to original article contains verified protocol PubMed

Sirolimus & Vorinostat

back to top

Regimen

Study	Evidence
Janku et al. 2014	Non-randomized

This is a very heavily pre-treated cohort, median of 6 prior therapies; doses here are one level below MTD and are proposed as the ongoing doses to be studied.

Chemotherapy

Sirolimus (Rapamune) 4 mg PO once per day
Vorinostat (Zolinza) as follows:
- Cycle 1: 300 mg once per day on days 7 to 28
- Subsequent cycles: 300 mg once per day on days 1 to 28

28-day cycles

References

Abstract: Filip Janku, Yasuhiro Oki, Gerald Steven Falchook, Vivek Subbiah, Aung Naing, Vivianne Marie Velez Bravo, David S. Hong, Jason R. Westin, Cesar Nunez, Luis Fayad, Sattva Swarup Neelapu, Larry W. Kwak, Elizabeth J. Shpall, Jennifer J. Wheler, Tamara Barnes, Winnie S. Liang, Bodour Salhia, Funda Meric-Bernstam, Razelle Kurzrock, Michelle A. Fanale. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. J Clin Oncol 32:5s, 2014 (suppl; abstr 8508) link to original abstract

Vinblastine (Velban)

back to top

Regimen

Study	Evidence
Little et al. 1998	Retrospective

This is a retrospective study; we are not aware of a prospective trial of vinblastine monotherapy in this setting.

Chemotherapy

Vinblastine (Velban) 4 to 6 mg/m² IV once on day 1

1 to 2-week cycles

References

Retrospective: Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol. 1998 Feb;16(2):584-8. link to original article PubMed

Vinorelbine (Navelbine)

back to top

Regimen

Study	Evidence
Devizzi et al. 1994	Phase II

Chemotherapy

Vinorelbine (Navelbine) 30 mg/m² IV bolus once per week

Complete responders received 6 additional doses past CR; others continued until progression or a maximum of 24 doses

References

Devizzi L, Santoro A, Bonfante V, Viviani S, Balzarini L, Valagussa P,vBonadonna G. Vinorelbine: an active drug for the management of patients withvheavily pretreated Hodgkin's disease. Ann Oncol. 1994 Nov;5(9):817-20. link to original article contains verified protocol PubMed

Consolidation and/or maintenance after salvage therapy

Allogeneic hematopoietic cell transplant

Usually reserved for patients relapsing after autologous hematopoietic cell transplant, and then for younger and very fit individuals. The regimens below have been specifically studied in the setting of relapsed/refractory Hodgkin lymphoma; for other regimens please go to the transplant conditioning regimens page.

Regimen #1

To be completed. Treatment preceded by salvage brentuximab vedotin.

Regimen #2

Study	Evidence
Sureda et al. 2011	Phase II

Treatment preceded by DHAP x 2.

Preparative regimen

Fludarabine (Fludara) 150 mg/m² IV once per day on days -8 to -4
Melphalan (Alkeran) 140 mg/m² IV once per day on days -3 & -2

Recipients of hematopoietic cells from matched unrelated donors also received:

Antithymocyte globulin (ATG) 45 mg/kg IV once per day on days -4 to -2

Graft-versus-host disease prophylaxis

Cyclosporine A (not specified whether modified or non-modified) starting on day -2 at 1.5 mg/kg IV BID
Methotrexate (MTX) 10 mg/m² IV once per day on days +1, +3, +6, +11

If no acute GVHD of grade 2 or more, cyclosporine A is tapered down by 10% per week starting on day +90 with planned discontinuation by day +180.

Regimen #3

Study	Evidence
Anderlini et al. 2008	Phase II

Patients had "chemosensitive or stable disease after salvage treatment." The regimen as reported here is what the authors were using towards the end of the study period; see paper for details.

Preparative regimen

Fludarabine (Fludara) 33 mg/m² IV once per day on days -5 to -2
Melphalan (Alkeran) 70 mg/m² IV once per day on days -3 & -2

Recipients of hematopoietic cells from matched unrelated donors also received:

Antithymocyte globulin (ATG) 2 mg/kg IV once per day on days -4 to -2

Graft-versus-host disease prophylaxis

Tacrolimus (Prograf) IV starting on day -2, dosed to achieve serum levels 4–12 ng/mL and switched to PO as soon as possible. Continued for at least 6 months and then "tapered off" (instructions not given).
Methotrexate (MTX) 5 mg/m² IV once per day on days +1, +3, +6 (extra dose on day +11 for MUD recipients)

Regimen #4

Study	Evidence
Sobol et al. 2013	Phase II

BEAM is the preparative regimen; further details not available in the abstract.

References

Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83. link to original article contains protocol PubMed
Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008 Feb;93(2):257-64. Epub 2008 Jan 26. link to original article contains verified protocol PubMed
Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ, García-Noblejas A, López Corral L, Xicoy B, Sierra J, Schmitz N. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012 Feb;97(2):310-7. Epub 2011 Oct 11. link to original article contains verified protocol PubMed
Sobol U, Rodriguez T, Smith S, Go A, Vimr R, Parthasarathy M, Guo R, Stiff P. Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease. Leuk Lymphoma. 2014 Jun;55(6):1281-7. Epub 2013 Oct 3. link to original article PubMed
Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, Shustov AR, Tilly H, Trippett TM, Gibb A, Grove LE, Advani R. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015 Mar;56(3):703-10. Epub 2015 Jan 21 link to original article PubMed

Autologous hematopoietic cell transplant

To be completed. Usually preceded by a high-intensity salvage chemotherapy. See details about preparative regimens.

Patients in AETHERA were randomized to brentuximab vedotin maintenance versus observation.

References

Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, Sebban C, Voillat L, Casasnovas O, Stamatoullas A, Bouabdallah K, André M, Jais JP, Cazals-Hatem D, Gisselbrecht C; GELA/SFGM Study Group. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008 Dec 20;26(36):5980-7. Epub 2008 Nov 17. link to original article PubMed
1. Update: Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marçais A, Deau-Fischer B, Bouabdallah R, Sebban C, Salles G, Brice P. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica. 2016 Apr;101(4):474-81. Epub 2015 Dec 31. link to original article PubMed
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62. Epub 2015 Mar 18. Erratum in: Lancet. 2015 Aug 8;386(9993):532. link to original article contains verified protocol PubMed

Brentuximab vedotin (Adcetris)

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Moskowitz et al. 2015 (AETHERA)	Phase III	Placebo	Superior PFS

Treatment begins 30 to 45 days after autologous hematopoietic cell transplant.

Chemotherapy

Brentuximab vedotin (Adcetris) 1.8 mg/kg IV once on day 1

3-week cycle for 16 cycles

References

Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62. Epub 2015 Mar 18. Erratum in: Lancet. 2015 Aug 8;386(9993):532. link to original article contains verified protocol PubMed

Observation

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Moskowitz et al. 2015 (AETHERA)	Phase III	Brentuximab vedotin	Inferior PFS

No further treatment after autologous hematopoietic cell transplant.

References

Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62. Epub 2015 Mar 18. Erratum in: Lancet. 2015 Aug 8;386(9993):532. link to original article contains verified protocol PubMed

Response criteria

NCI Sponsored International Working Group Criteria (1999)

Intended for non-Hodgkin lymphoma (NHL) but often referred to in the Hodgkin lymphoma literature.

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr;17(4):1244. Review. Erratum in: J Clin Oncol 2000 Jun;18(11):2351. link to original article PubMed

Juweid's criteria (2007)

Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007 Feb 10;25(5):571-8. Epub 2007 Jan 22. link to original article PubMed

Deauville criteria (2010)

Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, Almquist H, Loft A, Højgaard L, Federico M, Gallamini A, Smith P, Johnson P, Radford J, O'Doherty MJ. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1824-33. Epub 2010 May 27. link to original article PubMed
Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, Meignan M, Malkowski B, Hofman MS, Barrington SF. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013 May;54(5):683-90. Epub 2013 Mar 20. link to original article PubMed

Investigational agents

Fotemustine (Muphoran)

@@ Line 1: / Line 1: @@
 '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].'''
-Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]]. ''Are you looking for a regimen but can't find it here? It is possible that we've moved it to the [[Hodgkin_lymphoma_-_obsolete|obsolete regimens page]]. If you still can't find it, please let us know so we can add it!''
+Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. ''Are you looking for a regimen but can't find it here? It is possible that we've moved it to the [[Hodgkin_lymphoma_-_obsolete|obsolete regimens page]]. If you still can't find it, please let us know so we can add it!''
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
-|<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div>
+|<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div>
-<div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} variants on this page</b></font></div>
+<div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div>
 |}
 {{TOC limit|limit=3}}
@@ Line 68: / Line 68: @@
 *[[Example orders for ABVD in Hodgkin lymphoma]]
-===Regimen {{#subobject:8903e6|Variant=1}}===
+===Regimen #1, ABVD x 2 -> IFRT {{#subobject:c39ab4|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
@@ Line 75: / Line 75: @@
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://jco.ascopubs.org/content/22/14/2835.long Bonadonna et al. 2004]
+|[http://www.nejm.org/doi/full/10.1056/NEJMoa1000067 Engert et al. 2010 (GHSG HD10)]
 |style="background-color:#00cd00"|Phase III
-|ABVD x 4 -> IFRT<br> ABVD x 4 -> STNI
+|ABVD x 4 -> IFRT
-|
+|style="background-color:#eeee00"|Seems not superior
 |-
-|[http://jco.ascopubs.org/content/25/23/3495.long Engert et al. 2007 (GHSG HD7)]
+|rowspan=3|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext Behringer et al. 2014 (GHSG HD13)]
-|style="background-color:#00cd00"|Phase III
+|rowspan=3 style="background-color:#00cd00"|Phase III
-|Radiation therapy
+|ABV -> IFRT
-|
+|style="background-color:#00cd00"|Superior FFTF
 |-
-|[http://www.nejm.org/doi/full/10.1056/NEJMoa1000067 Engert et al. 2010 (GHSG HD10)]
+|AV -> IFRT
-|style="background-color:#00cd00"|Phase III
+|style="background-color:#00cd00"|Superior FFTF
-|ABVD -> RT (various combinations)
-|
 |-
-|[http://jco.ascopubs.org/content/32/12/1188.long Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)]
+|[[#AVD_-.3E_IFRT|AVD -> IFRT]]
-|style="background-color:#00cd00"|Phase III
+|style="background-color:#00cd00"|Might have superior FFTF
-|[[Hodgkin_lymphoma#ABVD|ABVD x 4]]
-|style="background-color:#eeee00"|Inconclusive whether non-inferior
 |-
-|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext Behringer et al. 2014 (GHSG HD13)]
+|}
-|style="background-color:#00cd00"|Phase III
+====Chemotherapy====
-|ABV -> IFRT<br> AV -> IFRT<br> [[#AVD_-.3E_IFRT|AVD -> IFRT]]
+*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
-|
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
+'''4-week cycle for 2 cycles, followed by IFRT (see individual protocols for details)'''
+===Regimen #2, ABVD x 3 -> IFRT {{#subobject:25de6e|Variant=1}}===
+{| border="1" style="text-align:center;" !align="left"
+|'''Study'''
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+|'''Comparator'''
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
 |[http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/547 Radford et al. 2015 (UK NCRI RAPID)]
@@ Line 112: / Line 119: @@
 *[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-'''4-week cycles, see note:'''
+'''4-week cycle for 3 cycles, followed by IFRT (see note)'''
-''Note: Patients in '''Bonadonna et al. 2004''' received 4 cycles of ABVD followed by STNI versus IFRT. Patients in '''EORTC/LYSA/FIL H10''' received 2 cycles of ABVD followed by interim PET-CT; those with a negative interim PET-CT (1 or 2 points on the 5-point Deauville scale) were randomized to receive 2 more cycles of ABVD versus 1 more cycle of ABVD followed by INRT 30 Gy (+ 6 Gy boost); those with a positive PET-CT proceeded to receive escalated BEACOPP followed by INRT 30 Gy (+ 6 Gy boost). Patients in '''GHSG HD13''' received 2 cycles of ABVD followed by 30 Gy involved-field radiotherapy (IFRT). Patients in '''UK NCRI RAPID''' received 3 cycles of ABVD followed by interim PET-CT; those with a negative PET-CT after the 3rd cycle (1 or 2 points on the 5-point Deauville scale) were randomized to receive IFRT versus no further treatment; those with a positive PET-CT proceeded to receive one more cycle of ABVD followed by IFRT.''
+''Note: Patients in '''UK NCRI RAPID''' received 3 cycles of ABVD followed by interim PET-CT; those with a negative PET-CT after the 3rd cycle (1 or 2 points on the 5-point Deauville scale) were randomized to receive IFRT versus no further treatment; those with a positive PET-CT proceeded to receive one more cycle of ABVD followed by IFRT.''
-===References===
+===Regimen #3, ABVD x 3 -> INRT {{#subobject:465f05|Variant=1}}===
-# Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004 Jul 15;22(14):2835-41. [http://jco.ascopubs.org/content/22/14/2835.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15199092 PubMed]
+{| border="1" style="text-align:center;" !align="left"
-# Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007 Aug 10;25(23):3495-502. [http://jco.ascopubs.org/content/25/23/3495.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17606976 PubMed]
+|'''Study'''
-# Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 Aug 12;363(7):640-52. [http://www.nejm.org/doi/full/10.1056/NEJMoa1000067 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20818855 PubMed]
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-## '''Sub-group analysis:''' Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.[http://www.bloodjournal.org/content/127/18/2189.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26834240 PubMed]
+|'''Comparator'''
-<!-- Presented (preliminary results) at the 51st Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA, December 5-8, 2009; Eighth International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 23-26, 2010; and 54th ASH Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
-# Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. [http://jco.ascopubs.org/content/32/12/1188.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637998 PubMed]
-# Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from  the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015 Apr 11;385(9976):1418-27. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25539730 PubMed]
-## '''Sub-group analysis:''' Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.[http://www.bloodjournal.org/content/127/18/2189.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26834240 PubMed]
-<!-- # '''Abstract:''' Radford, John, Barrington, Sally, Counsell, Nicholas, Pettengell, Ruth, Johnson, Peter, Wimperis, Jennie, Coltart, Stewart, Culligan, Dominic, Lister, Andrew, Bessell, Eric, Kruger, Anton, Popova, Bilyana, Hancock, Barry, Hoskin, Peter, Illidge, Timothy, O'Doherty, Michael. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts 2012 120: 547 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/547 link to original abstract] -->
-# Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. [http://www.nejm.org/doi/full/10.1056/NEJMoa1408648 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25901426 PubMed]
-==AVD -> IFRT {{#subobject:7e0834|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
-AVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine<br>
-IFRT: '''<u>I</u>'''nvolved '''<u>F</u>'''ield '''<u>R</u>'''adiation '''<u>T</u>'''herapy
-===Regimen {{#subobject:635312|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
-|'''Study'''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|'''Comparator'''
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext Behringer et al. 2014 (GHSG HD13)]
+|[http://jco.ascopubs.org/content/32/12/1188.long Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)]
 |style="background-color:#00cd00"|Phase III
-|ABV -> IFRT<br> [[#ABVD_-.3E_RT|ABVD -> IFRT]]<br> AV -> IFRT
+|[[Hodgkin_lymphoma#ABVD|ABVD x 4]]
-|
+|style="background-color:#eeee00"|Inconclusive whether non-inferior
 |-
 |}
 ====Chemotherapy====
 *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-'''4-week cycles'''
+'''4-week cycle for 3 cycles, followed by INRT (see note)'''
-''Chemotherapy is followed by IFRT.''
+''Note: Patients in '''EORTC/LYSA/FIL H10''' received 2 cycles of ABVD followed by interim PET-CT; those with a negative interim PET-CT (1 or 2 points on the 5-point Deauville scale) were randomized to receive 2 more cycles of ABVD versus 1 more cycle of ABVD followed by INRT 30 Gy (+ 6 Gy boost); those with a positive PET-CT proceeded to receive [[#BEACOPP.2C_escalated_dose_2|escalated BEACOPP]] followed by INRT 30 Gy (+ 6 Gy boost).''
-===References===
+===Regimen #4, ABVD x 4 -> IFRT {{#subobject:8903e6|Variant=1}}===
-# Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from  the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015 Apr 11;385(9976):1418-27. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25539730 PubMed]
+{| border="1" style="text-align:center;" !align="left"
-## '''Sub-group analysis:''' Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.[http://www.bloodjournal.org/content/127/18/2189.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26834240 PubMed]
+|'''Study'''
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-==MOPP-ABV -> IFRT {{#subobject:09f0a5|Regimen=1}}==
+|'''Comparator'''
-{| class="wikitable" style="float:right; margin-left: 5px;"
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
+|-
+|[http://jco.ascopubs.org/content/22/14/2835.long Bonadonna et al. 2004]
+|style="background-color:#00cd00"|Phase III
+|ABVD x 4 -> STNI
+|style="background-color:#eeee00"|Seems not superior
+|-
+|[http://www.nejm.org/doi/full/10.1056/NEJMoa1000067 Engert et al. 2010 (GHSG HD10)]
+|style="background-color:#00cd00"|Phase III
+|ABVD x 2 -> IFRT
+|style="background-color:#eeee00"|Seems not superior
+|-
+|[http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/547 Radford et al. 2015 (UK NCRI RAPID)]
+|style="background-color:#eeee00"|Non-randomized portion of RCT
+|style="background-color:#d3d3d3"|
+|style="background-color:#d3d3d3"|
 |-
-|[[#top|back to top]]
 |}
-MOPP: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
+''Note: Patients in '''UK NCRI RAPID''' received 3 cycles of ABVD followed by interim PET-CT; those with a positive PET-CT proceeded to receive a fourth cycle of ABVD followed by IFRT.''
-<br>ABV: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine
+====Chemotherapy====
-<br>IFRT: '''<u>I</u>'''nvolved '''<u>F</u>'''ield '''<u>R</u>'''adiation '''<u>T</u>'''herapy
+*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
+'''4-week cycle for 4 cycles, followed by IFRT (see individual protocols for details)'''
-===Regimen {{#subobject:0e0363|Variant=1}}===
+===Regimen #5, ABVD x 2 -> EFRT {{#subobject:54497b|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
@@ Line 178: / Line 185: @@
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-F)]
+|[http://jco.ascopubs.org/content/25/23/3495.long Engert et al. 2007 (GHSG HD7)]
 |style="background-color:#00cd00"|Phase III
-|Subtotal nodal radiotherapy
+|EFRT
-|style="background-color:#00cd00"|Superior OS
+|style="background-color:#00cd00"|Superior FFTF
 |-
 |}
 ====Chemotherapy====
-*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
+*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose is capped at 2 mg) IV once on day 1
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
+*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
+*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 8
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
-*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8
-'''4-week cycle for 3 cycles'''
-''Chemotherapy is followed in 3 to 4 weeks by IFRT; see text for details.''
-===References===
+'''4-week cycle for 2 cycles, followed by EFRT (30 Gy + 10 Gy to the involved field)'''
-# Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. [http://www.nejm.org/doi/full/10.1056/NEJMoa064601 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/17989384 PubMed]
-=Untreated, early-stage unfavorable=
+===Regimen #6, ABVD x 4 -> STNI {{#subobject:9f26c9|Variant=1}}===
-''Definitions of favorable/unfavorable risk factors vary somewhat across sites; see original sources for details.''
-==ABVD {{#subobject:0e1f18|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
-ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
-===Example orders===
-*[[Example orders for ABVD in Hodgkin lymphoma]]
-===Regimen {{#subobject:865dd5|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
@@ Line 220: / Line 206: @@
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://jco.ascopubs.org/content/32/12/1188.long Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)]
+|[http://jco.ascopubs.org/content/22/14/2835.long Bonadonna et al. 2004]
 |style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#ABVD_-.3E_RT_2|ABVD x 4 -> INRT]]
+|ABVD x 4 -> IFRT
-|style="background-color:#eeee00"|Inconclusive whether non-inferior
+|style="background-color:#eeee00"|Seems not superior
 |-
 |}
@@ Line 232: / Line 218: @@
 *[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-'''4-week cycle for 2 cycles, then:'''
+'''4-week cycle for 4 cycles, followed by STNI'''
-''Patients with a negative interim PET-CT (1 or 2 points on the 5-point Deauville scale) were randomized to receive 4 more cycles of ABVD versus 2 more cycles of ABVD followed by INRT 30 Gy (+ 6 Gy boost). Patients with a positive PET-CT proceeded to receive escalated BEACOPP followed by INRT 30 Gy (+ 6 Gy boost).''
 ===References===
+# Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004 Jul 15;22(14):2835-41. [http://jco.ascopubs.org/content/22/14/2835.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15199092 PubMed]
+# Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007 Aug 10;25(23):3495-502. [http://jco.ascopubs.org/content/25/23/3495.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17606976 PubMed]
+# Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 Aug 12;363(7):640-52. [http://www.nejm.org/doi/full/10.1056/NEJMoa1000067 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20818855 PubMed]
+## '''Sub-group analysis:''' Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.[http://www.bloodjournal.org/content/127/18/2189.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26834240 PubMed]
 <!-- Presented (preliminary results) at the 51st Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA, December 5-8, 2009; Eighth International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 23-26, 2010; and 54th ASH Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
 # Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. [http://jco.ascopubs.org/content/32/12/1188.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637998 PubMed]
+# Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015 Apr 11;385(9976):1418-27. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25539730 PubMed]
+## '''Sub-group analysis:''' Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.[http://www.bloodjournal.org/content/127/18/2189.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26834240 PubMed]
+<!-- # '''Abstract:''' Radford, John, Barrington, Sally, Counsell, Nicholas, Pettengell, Ruth, Johnson, Peter, Wimperis, Jennie, Coltart, Stewart, Culligan, Dominic, Lister, Andrew, Bessell, Eric, Kruger, Anton, Popova, Bilyana, Hancock, Barry, Hoskin, Peter, Illidge, Timothy, O'Doherty, Michael. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts 2012 120: 547 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/547 link to original abstract] -->
+# Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. [http://www.nejm.org/doi/full/10.1056/NEJMoa1408648 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25901426 PubMed]
-==ABVD -> RT {{#subobject:b830d7|Regimen=1}}==
+==AVD -> IFRT {{#subobject:7e0834|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
 |[[#top|back to top]]
 |}
-ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine<br>
+AVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine<br>
-RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
+IFRT: '''<u>I</u>'''nvolved '''<u>F</u>'''ield '''<u>R</u>'''adiation '''<u>T</u>'''herapy
-===Example orders===
+===Regimen {{#subobject:635312|Variant=1}}===
-*[[Example orders for ABVD in Hodgkin lymphoma]]
-===Regimen {{#subobject:44b42c|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
@@ Line 258: / Line 247: @@
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://jco.ascopubs.org/content/28/27/4199.long Eich et al. 2010 (GHSG HD11)]
+|rowspan=3|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext Behringer et al. 2014 (GHSG HD13)]
-|style="background-color:#00cd00"|Phase III
+|rowspan=3 style="background-color:#00cd00"|Phase III
-|[[#BEACOPP_-.3E_IFRT|BEACOPP -> IFRT]]
+|ABV -> IFRT
-|style="background-color:#eeee00"|Seems not superior
+|style="background-color:#d3d3d3"|Not reported
 |-
-|[http://jco.ascopubs.org/content/30/9/907.long von Tresckow et al. 2012 (GHSG HD14)]
+|[[#ABVD_-.3E_RT|ABVD -> IFRT]]
-|style="background-color:#00cd00"|Phase III
+|style="background-color:#ff0000"|Might have inferior FFTF
-|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_-.3E_ABVD_-.3E_RT|BEACOPPesc x 2 -> ABVD x 2 -> IFRT]]
-|style="background-color:#ff0000"|Inferior FFTF
 |-
-|[http://jco.ascopubs.org/content/32/12/1188.long Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)]
+|AV -> IFRT
-|style="background-color:#00cd00"|Phase III
+|style="background-color:#d3d3d3"|Not reported
-|[[Hodgkin_lymphoma#ABVD_2|ABVD x 6]]
-|style="background-color:#eeee00"|Inconclusive whether noninferior
-|-
-|[http://jco.ascopubs.org/content/33/17/1936.full Advani et al. 2015 (ECOG E2496)]
-|style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#Stanford_V_-.3E_RT|Stanford V -> RT]]
-|style="background-color:#eeee00"|Seems not superior
 |-
 |}
 ====Chemotherapy====
 *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-'''4-week cycles, see note'''
+'''4-week cycles'''
-''Note: Patients in '''GHSG HD11''' received 4 cycles of ABVD followed by randomization to 20 Gy versus 30 Gy of IFRT. Patients in '''GHSG HD14''' received 4 cycles of ABVD followed by IFRT. Patients in '''EORTC/LYSA/FIL H10''' received 2 cycles of ABVD followed by interim PET-CT; those with a negative interim PET-CT (1 or 2 points on the 5-point Deauville scale) were randomized to receive 4 more cycles of ABVD versus 2 more cycles of ABVD followed by INRT 30 Gy (+ 6 Gy boost); those with a positive PET-CT proceeded to receive escalated BEACOPP followed by INRT 30 Gy (+ 6 Gy boost). Patients in '''E2496''' received 6 to 8 cycles of ABVD; all patients received 36 Gy IFRT to the mediastinum, hila, and supraclavicular regions two to three weeks after completion of chemotherapy.''
+''Chemotherapy is followed by IFRT.''
 ===References===
-# Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27):4199-206. Epub 2010 Aug 16. [http://jco.ascopubs.org/content/28/27/4199.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20713848 PubMed]
+# Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015 Apr 11;385(9976):1418-27. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25539730 PubMed]
-<!-- Presented in part at the 52nd Annual Meeting of the American Society of Hematology, December 4-7, 2010, Orlando, FL. -->
+## '''Sub-group analysis:''' Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.[http://www.bloodjournal.org/content/127/18/2189.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26834240 PubMed]
-# von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.  J Clin Oncol. 2012 Mar 20;30(9):907-13. Epub 2012 Jan 23. [http://jco.ascopubs.org/content/30/9/907.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22271480 PubMed]
-<!-- Presented (preliminary results) at the 51st Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA, December 5-8, 2009; Eighth International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 23-26, 2010; and 54th ASH Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
-# Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. [http://jco.ascopubs.org/content/32/12/1188.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637998 PubMed]
-# Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42. Epub 2015 Apr 20. [http://jco.ascopubs.org/content/33/17/1936.full link to original article] '''contains limited protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25897153 PubMed]
-==BEACOPP -> IFRT {{#subobject:053c14|Regimen=1}}==
+==MOPP-ABV -> IFRT {{#subobject:09f0a5|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
 |[[#top|back to top]]
 |}
-BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
+MOPP: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
+<br>ABV: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine
 <br>IFRT: '''<u>I</u>'''nvolved '''<u>F</u>'''ield '''<u>R</u>'''adiation '''<u>T</u>'''herapy
-===Example orders===
+===Regimen {{#subobject:0e0363|Variant=1}}===
-*[[Example orders for BEACOPP in Hodgkin lymphoma]]
-===Regimen {{#subobject:9b724c|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
@@ Line 315: / Line 288: @@
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://jco.ascopubs.org/content/28/27/4199.long Eich et al. 2010 (GHSG HD11)]
+|[http://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-F)]
 |style="background-color:#00cd00"|Phase III
-|[[#ABVD_-.3E_RT_2|ABVD -> IFRT]]
+|Subtotal nodal radiotherapy
-|style="background-color:#eeee00"|Seems not superior
+|style="background-color:#00cd00"|Superior OS
 |-
 |}
 ====Chemotherapy====
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
-*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose is capped at 2 mg) IV once on day 1
-*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
-*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg) IV once on day 8
 *[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
 *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
+*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 8
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8
+'''4-week cycle for 3 cycles'''
-'''3-week cycle for 4 cycles'''
+''Chemotherapy is followed in 3 to 4 weeks by IFRT; see text for details.''
-''Patients were then randomized to receive 20 Gy versus 30 Gy of IFRT.''
 ===References===
-# Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27):4199-206. Epub 2010 Aug 16. [http://jco.ascopubs.org/content/28/27/4199.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20713848 PubMed]
+# Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. [http://www.nejm.org/doi/full/10.1056/NEJMoa064601 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/17989384 PubMed]
+=Untreated, early-stage unfavorable=
+''Definitions of favorable/unfavorable risk factors vary somewhat across sites; see original sources for details.''
-==BEACOPP, escalated -> ABVD -> RT {{#subobject:e0cab9|Regimen=1}}==
+==ABVD {{#subobject:0e1f18|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
 |[[#top|back to top]]
 |}
-BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone<br>
+ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
-ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine<br>
-RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
+===Example orders===
+*[[Example orders for ABVD in Hodgkin lymphoma]]
-===Regimen {{#subobject:7d82bc|Variant=1}}===
+===Regimen {{#subobject:865dd5|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
@@ Line 353: / Line 330: @@
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://jco.ascopubs.org/content/30/9/907.long von Tresckow et al. 2012 (GHSG HD14)]
+|[http://jco.ascopubs.org/content/32/12/1188.long Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)]
 |style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#ABVD_-.3E_RT_2|ABVD x 4 -> IFRT]]
+|[[Hodgkin_lymphoma#ABVD_-.3E_RT_2|ABVD x 4 -> INRT]]
-|style="background-color:#00cd00"|Superior FFTF
+|style="background-color:#eeee00"|Inconclusive whether non-inferior
 |-
 |}
-====Chemotherapy, escalated BEACOPP portion====
+====Chemotherapy====
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
-*[[Cyclophosphamide (Cytoxan)]] 1250 mg/m<sup>2</sup> IV once on day 1
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg per cycle) IV once on day 8
-*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
-*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
-====Supportive medications====
-*[[Filgrastim (Neupogen)]] (dose not specified) SC once per day starting on day 8, continues until ANC > 1000/uL for 3 consecutive days
-'''3-week cycle for 2 cycles, followed by:'''
-====Chemotherapy, ABVD portion====
-*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-'''4-week cycle for 2 cycles'''
+'''4-week cycle for 2 cycles, then:'''
-''Treatment was followed by radiation therapy to the involved fields.''
+''Patients with a negative interim PET-CT (1 or 2 points on the 5-point Deauville scale) were randomized to receive 4 more cycles of ABVD versus 2 more cycles of ABVD followed by INRT 30 Gy (+ 6 Gy boost). Patients with a positive PET-CT proceeded to receive escalated BEACOPP followed by INRT 30 Gy (+ 6 Gy boost).''
 ===References===
-<!-- Presented in part at the 52nd Annual Meeting of the American Society of Hematology, December 4-7, 2010, Orlando, FL. -->
+<!-- Presented (preliminary results) at the 51st Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA, December 5-8, 2009; Eighth International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 23-26, 2010; and 54th ASH Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
-# von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.  J Clin Oncol. 2012 Mar 20;30(9):907-13. Epub 2012 Jan 23. [http://jco.ascopubs.org/content/30/9/907.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22271480 PubMed]
+# Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. [http://jco.ascopubs.org/content/32/12/1188.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637998 PubMed]
-==BV + AVD -> ISRT {{#subobject:d609fa|Regimen=1}}==
+==ABVD -> RT {{#subobject:b830d7|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
 |[[#top|back to top]]
 |}
-BV + AVD: '''<u>B</u>'''rentuximab '''<u>V</u>'''edotin, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine<br>
+ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine<br>
-ISRT: '''<u>I</u>'''nvolved '''<u>S</u>'''ite '''<u>R</u>'''adiation '''<u>T</u>'''herapy
+RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
+===Example orders===
+*[[Example orders for ABVD in Hodgkin lymphoma]]
-===Regimen {{#subobject:dce193|Variant=1}}===
+===Regimen {{#subobject:44b42c|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
 |[[Levels_of_Evidence#Evidence|'''Evidence''']]
+|'''Comparator'''
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://www.bloodjournal.org/content/128/11/1458.long Kumar et al. 2016]
+|[http://jco.ascopubs.org/content/28/27/4199.long Eich et al. 2010 (GHSG HD11)]
-|style="background-color:#eeee00"|Phase II
+|style="background-color:#00cd00"|Phase III
+|[[#BEACOPP_-.3E_IFRT|BEACOPP -> IFRT]]
+|style="background-color:#eeee00"|Seems not superior
+|-
+|[http://jco.ascopubs.org/content/30/9/907.long von Tresckow et al. 2012 (GHSG HD14)]
+|style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_-.3E_ABVD_-.3E_RT|BEACOPPesc x 2 -> ABVD x 2 -> IFRT]]
+|style="background-color:#ff0000"|Inferior FFTF
+|-
+|[http://jco.ascopubs.org/content/32/12/1188.long Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)]
+|style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#ABVD_2|ABVD x 6]]
+|style="background-color:#eeee00"|Inconclusive whether noninferior
+|-
+|[http://jco.ascopubs.org/content/33/17/1936.full Advani et al. 2015 (ECOG E2496)]
+|style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#Stanford_V_-.3E_RT|Stanford V -> RT]]
+|style="background-color:#eeee00"|Seems not superior
 |-
 |}
 ====Chemotherapy====
-*[[Brentuximab vedotin (Adcetris)]] 1.2 mg/kg IV once per day on days 1 & 15
 *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-'''4-week cycle for 4 cycles'''
+'''4-week cycles, see note'''
-''Chemotherapy is followed by repeat PET-CT; patients with a negative PET-CT proceeded to receive 30 Gy of ISRT.''
+''Note: Patients in '''GHSG HD11''' received 4 cycles of ABVD followed by randomization to 20 Gy versus 30 Gy of IFRT. Patients in '''GHSG HD14''' received 4 cycles of ABVD followed by IFRT. Patients in '''EORTC/LYSA/FIL H10''' received 2 cycles of ABVD followed by interim PET-CT; those with a negative interim PET-CT (1 or 2 points on the 5-point Deauville scale) were randomized to receive 4 more cycles of ABVD versus 2 more cycles of ABVD followed by INRT 30 Gy (+ 6 Gy boost); those with a positive PET-CT proceeded to receive escalated BEACOPP followed by INRT 30 Gy (+ 6 Gy boost). Patients in '''E2496''' received 6 to 8 cycles of ABVD; all patients received 36 Gy IFRT to the mediastinum, hila, and supraclavicular regions two to three weeks after completion of chemotherapy.''
 ===References===
-# Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11):1458-64. Epub 2016 Jul 25. [http://www.bloodjournal.org/content/128/11/1458.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27458003 PubMed]
+# Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27):4199-206. Epub 2010 Aug 16. [http://jco.ascopubs.org/content/28/27/4199.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20713848 PubMed]
+<!-- Presented in part at the 52nd Annual Meeting of the American Society of Hematology, December 4-7, 2010, Orlando, FL. -->
+# von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012 Mar 20;30(9):907-13. Epub 2012 Jan 23. [http://jco.ascopubs.org/content/30/9/907.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22271480 PubMed]
+<!-- Presented (preliminary results) at the 51st Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA, December 5-8, 2009; Eighth International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 23-26, 2010; and 54th ASH Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
+# Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. [http://jco.ascopubs.org/content/32/12/1188.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637998 PubMed]
+# Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42. Epub 2015 Apr 20. [http://jco.ascopubs.org/content/33/17/1936.full link to original article] '''contains limited protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25897153 PubMed]
-==MOPP-ABV -> IFRT {{#subobject:2a2ed7|Regimen=1}}==
+==BEACOPP -> IFRT {{#subobject:053c14|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
 |[[#top|back to top]]
 |}
-MOPP: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
+BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
-<br>ABV: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine
 <br>IFRT: '''<u>I</u>'''nvolved '''<u>F</u>'''ield '''<u>R</u>'''adiation '''<u>T</u>'''herapy
-===Regimen #1 {{#subobject:ac2cb7|Variant=1}}===
+===Example orders===
+*[[Example orders for BEACOPP in Hodgkin lymphoma]]
+===Regimen {{#subobject:9b724c|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
@@ Line 433: / Line 425: @@
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-U)]
+|[http://jco.ascopubs.org/content/28/27/4199.long Eich et al. 2010 (GHSG HD11)]
 |style="background-color:#00cd00"|Phase III
-|MOPP-ABV x 6 -> IFRT<br> MOPP-ABV x 4 -> Subtotal nodal radiotherapy
+|[[#ABVD_-.3E_RT_2|ABVD -> IFRT]]
-|
+|style="background-color:#eeee00"|Seems not superior
 |-
 |}
 ====Chemotherapy====
-*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose is capped at 2 mg) IV once on day 1
+*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
+*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg) IV once on day 8
 *[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
 *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
-*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 8
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
-*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8
-'''4-week cycle for 4 cycles'''
+'''3-week cycle for 4 cycles'''
+''Patients were then randomized to receive 20 Gy versus 30 Gy of IFRT.''
-''Chemotherapy is followed in 3 to 4 weeks by IFRT; see text for details.''
+===References===
+# Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27):4199-206. Epub 2010 Aug 16. [http://jco.ascopubs.org/content/28/27/4199.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20713848 PubMed]
-===Regimen #2 {{#subobject:f688a4|Variant=1}}===
+==BEACOPP, escalated -> ABVD -> RT {{#subobject:e0cab9|Regimen=1}}==
-{| border="1" style="text-align:center;" !align="left"
+{| class="wikitable" style="float:right; margin-left: 5px;"
-|'''Study'''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|'''Comparator'''
-|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
-|-
-|[http://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-U)]
-|style="background-color:#00cd00"|Phase III
-|MOPP-ABV x 4 -> IFRT<br> MOPP-ABV x 4 -> Subtotal nodal radiotherapy
-|
-|-
-|}
-====Chemotherapy====
-*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose is capped at 2 mg) IV once on day 1
-*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
-*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
-*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 8
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
-*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8
-'''4-week cycle for 6 cycles'''
-''Chemotherapy is followed in 3 to 4 weeks by IFRT; see text for details.''
-===References===
-# Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. [http://www.nejm.org/doi/full/10.1056/NEJMoa064601 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/17989384 PubMed]
-==Stanford V -> RT {{#subobject:50d745|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
 |-
 |[[#top|back to top]]
 |}
+BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone<br>
+ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine<br>
 RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
-===Regimen {{#subobject:e33d2b|Variant=1}}===
+===Regimen {{#subobject:7d82bc|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
@@ Line 496: / Line 463: @@
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://jco.ascopubs.org/content/33/17/1936.full Advani et al. 2015 (E2496)]
+|[http://jco.ascopubs.org/content/30/9/907.long von Tresckow et al. 2012 (GHSG HD14)]
 |style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#ABVD_-.3E_RT_2|ABVD -> RT]]
+|[[Hodgkin_lymphoma#ABVD_-.3E_RT_2|ABVD x 4 -> IFRT]]
-|style="background-color:#eeee00"|Seems not superior
+|style="background-color:#00cd00"|Superior FFTF
 |-
 |}
+====Chemotherapy, escalated BEACOPP portion====
-''In Advani et al. 2015 the Stanford V regimen is described as "once per week for 12 weeks." However, the regimen has previously been described as being 4-week cycles for 3 cycles (same duration, but schedule is different). Until this discrepancy is resolved, we replicate the 4-week cycle version here:''
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
-====Chemotherapy====
+*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
+*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 1250 mg/m<sup>2</sup> IV once on day 1
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg per cycle) IV once on day 8
+*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
+*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
+====Supportive medications====
+*[[Filgrastim (Neupogen)]] (dose not specified) SC once per day starting on day 8, continues until ANC > 1000/uL for 3 consecutive days
+'''3-week cycle for 2 cycles, followed by:'''
+====Chemotherapy, ABVD portion====
 *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
+*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Etoposide (Vepesid)]] 60 mg/m<sup>2</sup> IV once per day on days 15 & 16
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum of 2mg in any individual dose) IV once per day on days 8 & 22
-*[[Bleomycin (Blenoxane)]] 5 units/m<sup>2</sup> IV once per day on days 8 & 22
-*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO every other day (with taper)
-'''4-week cycle for 3 cycles'''
+'''4-week cycle for 2 cycles'''
-''All patients received 36 Gy IFRT to the mediastinum, hila, and supraclavicular regions two to three weeks after completion of chemotherapy, with additional IFRT to additional sites ≥ 5 cm (details not described).''
+''Treatment was followed by radiation therapy to the involved fields.''
 ===References===
-# Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42. Epub 2015 Apr 20. [http://jco.ascopubs.org/content/33/17/1936.full link to original article] '''contains limited protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25897153 PubMed]
+<!-- Presented in part at the 52nd Annual Meeting of the American Society of Hematology, December 4-7, 2010, Orlando, FL. -->
+# von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012 Mar 20;30(9):907-13. Epub 2012 Jan 23. [http://jco.ascopubs.org/content/30/9/907.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22271480 PubMed]
-=Untreated, advanced stage=
+==BV + AVD -> ISRT {{#subobject:d609fa|Regimen=1}}==
-''Generally defined as stage III/IV or stage II with bulky disease. Definitions for bulky disease vary across sites; see original sources for details,''
-==ABVD {{#subobject:8b9772|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
 |[[#top|back to top]]
 |}
-ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
+BV + AVD: '''<u>B</u>'''rentuximab '''<u>V</u>'''edotin, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine<br>
+ISRT: '''<u>I</u>'''nvolved '''<u>S</u>'''ite '''<u>R</u>'''adiation '''<u>T</u>'''herapy
-===Example orders===
+===Regimen {{#subobject:dce193|Variant=1}}===
-*[[Example orders for ABVD in Hodgkin lymphoma]]
-===Regimen #1, PET-adapted {{#subobject:a8fbc8|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
 |[[Levels_of_Evidence#Evidence|'''Evidence''']]
 |-
-|[http://jco.ascopubs.org/content/34/12/1376.full Zinzani et al. 2016 (HD0801)]
+|[http://www.bloodjournal.org/content/128/11/1458.long Kumar et al. 2016]
-|style="background-color:#eeee00"|Non-randomized
-|-
-|[http://jco.ascopubs.org/content/34/17/2020.full Press et al. 2016 (SWOG S0816)]
 |style="background-color:#eeee00"|Phase II
-|-
-|[http://www.nejm.org/doi/full/10.1056/NEJMoa1510093 Johnson et al. 2016 (RATHL)]
-|style="background-color:#eeee00"|Non-randomized portion of RCT
 |-
 |}
 ====Chemotherapy====
+*[[Brentuximab vedotin (Adcetris)]] 1.2 mg/kg IV once per day on days 1 & 15
 *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-'''4-week cycle for 2 cycles, followed by:'''
+'''4-week cycle for 4 cycles'''
+''Chemotherapy is followed by repeat PET-CT; patients with a negative PET-CT proceeded to receive 30 Gy of ISRT.''
-*'''HD0801:''' ''Patients underwent interim PET-CT after 2 cycles; those with a negative PET-CT by [[#Juweid.27s_criteria_.282007.29|Juweid's criteria]] received 4 more cycles of ABVD (6 total) and those with initial bulky disease were then randomized to RT versus no further treatment. Those with a positive PET-CT by [[#Juweid.27s_criteria_.282007.29|Juweid's criteria]] proceeded to [[#IGEV|salvage IGEV]].
+===References===
-*'''SWOG S0816:''' ''Patients underwent interim PET-CT after 2 cycles; those with a negative PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (1 to 3) received 4 more cycles of ABVD (6 total); those with a positive PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (4 or 5) proceeded to [[#BEACOPP.2C_escalated_dose_2|salvage escalated BEACOPP]].''
+# Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11):1458-64. Epub 2016 Jul 25. [http://www.bloodjournal.org/content/128/11/1458.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27458003 PubMed]
-*'''RATHL:''' ''Patients underwent interim PET-CT after 2 cycles; those with a negative PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (1 to 3) were randomized to 4 more cycles of ABVD (6 total) versus 4 cycles of [[#AVD|AVD]]; those with a positive PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (4 or 5) proceeded to [[#BEACOPP.2C_escalated_dose_2|salvage escalated BEACOPP]] or [[#BEACOPP-14_2|salvage BEACOPP-14]], specified in advance.''
-===Regimen #2, 8 cycles (ABVD<sub>8</sub>) {{#subobject:e8872e|Variant=1}}===
+==MOPP-ABV -> IFRT {{#subobject:2a2ed7|Regimen=1}}==
-{| border="1" style="text-align:center;" !align="left"
+{| class="wikitable" style="float:right; margin-left: 5px;"
-|'''Study'''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|'''Comparator'''
-|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[https://www.ncbi.nlm.nih.gov/pubmed/54209 Bonadonna et al. 1975]
+|[[#top|back to top]]
-|style="background-color:#00cd00"|Phase III
+|}
-|[[Hodgkin_lymphoma#MOPP|MOPP]]
+MOPP: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
-|style="background-color:#eeee00"|Seems not superior
+<br>ABV: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine
+<br>IFRT: '''<u>I</u>'''nvolved '''<u>F</u>'''ield '''<u>R</u>'''adiation '''<u>T</u>'''herapy
+===Regimen #1 {{#subobject:ac2cb7|Variant=1}}===
+{| border="1" style="text-align:center;" !align="left"
+|'''Study'''
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+|'''Comparator'''
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://jco.ascopubs.org/content/5/1/27.long Santoro et al. 1987]
+|rowspan=2|[http://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-U)]
-|style="background-color:#00cd00"|Phase III
+|rowspan=2 style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#MOPP|MOPP]]
+|MOPP-ABV x 6 -> IFRT
-|style="background-color:#00cd00"|Seems to have superior OS
-|-
-|[http://www.nejm.org/doi/full/10.1056/NEJM199211193272102 Canellos et al. 1992]
-|style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#MOPP|MOPP]]<br> [[Hodgkin_lymphoma#MOPP.2FABVD|MOPP/ABVD]]
-|
-|-
-|[http://jco.ascopubs.org/content/27/32/5390.long Hoskin et al. 2009 (UK NCRI ISRCTN 64141244)]
-|style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#Stanford_V|Stanford V]]
 |style="background-color:#eeee00"|Seems not superior
 |-
-|[http://www.nejm.org/doi/full/10.1056/NEJMoa1100340 Viviani et al. 2011]
+|MOPP-ABV x 4 -> STNI
-|style="background-color:#00cd00"|Phase III
-|[[#BEACOPP.2C_escalated_-.3E_BEACOPP|BEACOPP<sub>4+4</sub>]]
-|style="background-color:#ff0000"|Seems to have inferior FFFP
-|-
-|[http://jco.ascopubs.org/content/31/6/684.full Gordon et al. 2013 (E2496)]
-|style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#Stanford_V|Stanford V]]
 |style="background-color:#eeee00"|Seems not superior
 |-
-|[http://annonc.oxfordjournals.org/content/25/8/1622.full.html Mounier et al. 2014 (LYSA H34)]
+|}
-|style="background-color:#00cd00"|Phase III
+====Chemotherapy====
-|[[#BEACOPP.2C_escalated_-.3E_BEACOPP|BEACOPP<sub>4+4</sub>]]
+*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
-|style="background-color:#ff0000"|Might have inferior EFS
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose is capped at 2 mg) IV once on day 1
+*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
+*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
+*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 8
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8
+'''4-week cycle for 4 cycles'''
+''Chemotherapy is followed in 3 to 4 weeks by IFRT; see text for details.''
+===Regimen #2 {{#subobject:f688a4|Variant=1}}===
+{| border="1" style="text-align:center;" !align="left"
+|'''Study'''
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+|'''Comparator'''
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
+|-
+|rowspan=2|[http://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-U)]
+|rowspan=2 style="background-color:#00cd00"|Phase III
+|MOPP-ABV x 4 -> IFRT
+|style="background-color:#eeee00"|Seems not superior
 |-
-|[http://jco.ascopubs.org/content/34/17/2028.full Carde et al. 2016 (EORTC 20012)]
+|MOPP-ABV x 4 -> STNI
-|style="background-color:#00cd00"|Phase III
-|[[#BEACOPP.2C_escalated_-.3E_BEACOPP|BEACOPP<sub>4+4</sub>]]
 |style="background-color:#eeee00"|Seems not superior
 |-
 |}
 ====Chemotherapy====
-*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose is capped at 2 mg) IV once on day 1
-*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
-*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
+*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 8
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8
+'''4-week cycle for 6 cycles'''
-'''4-week cycle for 8 cycles'''
+''Chemotherapy is followed in 3 to 4 weeks by IFRT; see text for details.''
 ===References===
-# Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975 Jul;36(1):252-9. [https://www.ncbi.nlm.nih.gov/pubmed/54209 PubMed]
+# Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. [http://www.nejm.org/doi/full/10.1056/NEJMoa064601 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/17989384 PubMed]
-# Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987 Jan;5(1):27-37. [http://jco.ascopubs.org/content/5/1/27.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2433409 PubMed]
-# Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84. [http://www.nejm.org/doi/pdf/10.1056/NEJM199211193272102 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1383821 PubMed]
-# Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15;21(4):607-14. [http://jco.ascopubs.org/content/21/4/607.long link to original article] [https://www.ncbi.nlm.nih.gov/12586796 PubMed]
-# Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208-18. Epub 2005 Nov 28. [http://jco.ascopubs.org/content/23/36/9208.long link to original article] [https://www.ncbi.nlm.nih.gov/16314615 PubMed]
-<!-- Presented at the Annual Meeting of the American Society of Hematology, San Francisco, CA, December, 6-9, 2008; and in part at the 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, June, 7-11, 2005. -->
-# Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009 Nov 10;27(32):5390-6. Epub 2009 Sep 8. [http://jco.ascopubs.org/content/27/32/5390.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19738111 PubMed]
-# Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203-12. [http://www.nejm.org/doi/full/10.1056/NEJMoa1100340 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21774708 PubMed]
-# Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684-91. Epub 2012 Nov 26. [http://jco.ascopubs.org/content/31/6/684.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23182987 PubMed]
-## '''Subgroup analysis:''' Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013 Apr;161(1):76-86. Epub 2013 Jan 29. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906856/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23356491 PubMed]
-# Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). ABVD (8 cycles) versus BEACOPP (4 escalated cycles =4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014 Aug;25(8):1622-8. Epub 2014 May 14. [http://annonc.oxfordjournals.org/content/25/8/1622.full.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24827123 PubMed]
-# Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. J Clin Oncol. 2016 Apr 20;34(12):1376-85. Epub 2016 Feb 16. [http://jco.ascopubs.org/content/34/12/1376.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26884559 PubMed]
-# Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016 Jun 10;34(17):2020-7. Epub 2016 Apr 11. [http://jco.ascopubs.org/content/34/17/2020.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27069074 PubMed]
-# Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36. Epub 2016 Apr 25. [http://jco.ascopubs.org/content/34/17/2028.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27114593 PubMed]
-# Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. [http://www.nejm.org/doi/full/10.1056/NEJMoa1510093 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1510093/suppl_file/nejmoa1510093_protocol.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/27332902 PubMed]
-==ABVD, DD-DI {{#subobject:fb0584|Regimen=1}}==
+==Stanford V -> RT {{#subobject:50d745|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
 |[[#top|back to top]]
 |}
-ABVD, DD-DI: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine, '''<u>D</u>'''ose-'''<u>D</u>'''ense and '''<u>D</u>'''ose-'''<u>I</u>'''ntense
-===Regimen {{#subobject:bfb2a|Variant=1}}===
+RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
+===Regimen {{#subobject:e33d2b|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
 |[[Levels_of_Evidence#Evidence|'''Evidence''']]
+|'''Comparator'''
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://onlinelibrary.wiley.com/doi/10.1111/bjh.12862/full Russo et al. 2014]
+|[http://jco.ascopubs.org/content/33/17/1936.full Advani et al. 2015 (E2496)]
-|style="background-color:#eeee00"|Phase II
+|style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#ABVD_-.3E_RT_2|ABVD -> RT]]
+|style="background-color:#eeee00"|Seems not superior
 |-
 |}
+''In Advani et al. 2015 the Stanford V regimen is described as "once per week for 12 weeks." However, the regimen has previously been described as being 4-week cycles for 3 cycles (same duration, but schedule is different). Until this discrepancy is resolved, we replicate the 4-week cycle version here:''
 ====Chemotherapy====
-*[[Doxorubicin (Adriamycin)]] as follows:
+*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
-**Cycles 1 to 4: 35 mg/m<sup>2</sup> IV once per day on days 1 & 11
+*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
-**Cycles 5 & 6: 25 mg/m<sup>2</sup> IV once per day on days 1 & 11
+*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 11
+*[[Etoposide (Vepesid)]] 60 mg/m<sup>2</sup> IV once per day on days 15 & 16
-*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 11
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum of 2mg in any individual dose) IV once per day on days 8 & 22
-*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once on days 1 & 11
+*[[Bleomycin (Blenoxane)]] 5 units/m<sup>2</sup> IV once per day on days 8 & 22
+*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO every other day (with taper)
-====Supportive medications====
+'''4-week cycle for 3 cycles'''
-*[[Lenograstim (Granocyte)]] 263 µg SC once per day on days 6 to 8 and days 17 to 19 (6 doses per cycle)
-'''21-day cycle for 6 cycles'''
+''All patients received 36 Gy IFRT to the mediastinum, hila, and supraclavicular regions two to three weeks after completion of chemotherapy, with additional IFRT to additional sites ≥ 5 cm (details not described).''
 ===References===
-# Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A. A phase II study of dose-dense and dose-intense ABVD (ABVD(DD-DI) ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. Br J Haematol. 2014 Jul;166(1):118-29. Epub 2014 Mar 27. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.12862/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24673727 PubMed]
+# Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42. Epub 2015 Apr 20. [http://jco.ascopubs.org/content/33/17/1936.full link to original article] '''contains limited protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25897153 PubMed]
+=Untreated, advanced stage=
+''Generally defined as stage III/IV or stage II with bulky disease. Definitions for bulky disease vary across sites; see original sources for details,''
-==AVD {{#subobject:98fbb5|Regimen=1}}==
+==ABVD {{#subobject:8b9772|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
 |[[#top|back to top]]
 |}
-AVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
+ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
-===Regimen {{#subobject:75ea56|Variant=1}}===
+===Example orders===
+*[[Example orders for ABVD in Hodgkin lymphoma]]
+===Regimen #1, PET-adapted {{#subobject:a8fbc8|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
 |[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|'''Comparator'''
+|-
-|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
+|[http://jco.ascopubs.org/content/34/12/1376.full Zinzani et al. 2016 (HD0801)]
+|style="background-color:#eeee00"|Non-randomized
+|-
+|[http://jco.ascopubs.org/content/34/17/2020.full Press et al. 2016 (SWOG S0816)]
+|style="background-color:#eeee00"|Phase II
 |-
 |[http://www.nejm.org/doi/full/10.1056/NEJMoa1510093 Johnson et al. 2016 (RATHL)]
-|style="background-color:#00cd00"|Phase III
+|style="background-color:#eeee00"|Non-randomized portion of RCT
-|[[#ABVD_3|ABVD]]
-|style="background-color:#eeee00"|Inconclusive whether non-inferior
 |-
 |}
-''Treatment preceded by [[#ABVD_3|ABVD]] x 2.''
 ====Chemotherapy====
 *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
 *[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-'''4-week cycle for 4 cycles'''
+'''4-week cycle for 2 cycles, followed by:'''
-===References===
+*'''HD0801:''' ''Patients underwent interim PET-CT after 2 cycles; those with a negative PET-CT by [[#Juweid.27s_criteria_.282007.29|Juweid's criteria]] received 4 more cycles of ABVD (6 total) and those with initial bulky disease were then randomized to RT versus no further treatment. Those with a positive PET-CT by [[#Juweid.27s_criteria_.282007.29|Juweid's criteria]] proceeded to [[#IGEV|salvage IGEV]].
-# Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. [http://www.nejm.org/doi/full/10.1056/NEJMoa1510093 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1510093/suppl_file/nejmoa1510093_protocol.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/27332902 PubMed]
+*'''SWOG S0816:''' ''Patients underwent interim PET-CT after 2 cycles; those with a negative PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (1 to 3) received 4 more cycles of ABVD (6 total); those with a positive PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (4 or 5) proceeded to [[#BEACOPP.2C_escalated_dose_2|salvage escalated BEACOPP]].''
+*'''RATHL:''' ''Patients underwent interim PET-CT after 2 cycles; those with a negative PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (1 to 3) were randomized to 4 more cycles of ABVD (6 total) versus 4 cycles of [[#AVD|AVD]]; those with a positive PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (4 or 5) proceeded to [[#BEACOPP.2C_escalated_dose_2|salvage escalated BEACOPP]] or [[#BEACOPP-14_2|salvage BEACOPP-14]], specified in advance.''
-==BEACOPP {{#subobject:2720ea|Regimen=1}}==
+===Regimen #2, 8 cycles (ABVD<sub>8</sub>) {{#subobject:e8872e|Variant=1}}===
-{| class="wikitable" style="float:right; margin-left: 5px;"
+{| border="1" style="text-align:center;" !align="left"
+|'''Study'''
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+|'''Comparator'''
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[[#top|back to top]]
+|[https://www.ncbi.nlm.nih.gov/pubmed/54209 Bonadonna et al. 1975]
-|}
+|style="background-color:#00cd00"|Phase III
-BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
+|[[Hodgkin_lymphoma#MOPP|MOPP]]
+|style="background-color:#eeee00"|Seems not superior
-===Example orders===
-*[[Example orders for BEACOPP in Hodgkin lymphoma]]
-===Regimen {{#subobject:4e6661|Variant=1}}===
-{| border="1" style="text-align:center;" !align="left"
-|'''Study'''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|'''Comparator'''
-|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://annonc.oxfordjournals.org/content/8/2/143.long Diehl et al. 1997]
+|[http://jco.ascopubs.org/content/5/1/27.long Santoro et al. 1987]
-|style="background-color:#eeee00"|Non-randomized
+|style="background-color:#00cd00"|Phase III
-|style="background-color:#d3d3d3"|
+|[[Hodgkin_lymphoma#MOPP|MOPP]]
-|style="background-color:#d3d3d3"|
+|style="background-color:#00cd00"|Seems to have superior OS
 |-
-|rowspan=2|[http://jco.ascopubs.org/content/16/12/3810.long Diehl et al. 1998 (GHSG HD9)]
+|rowspan=2|[http://www.nejm.org/doi/full/10.1056/NEJM199211193272102 Canellos et al. 1992]
 |rowspan=2 style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_dose|Escalated dose BEACOPP]]
+|[[Hodgkin_lymphoma#MOPP|MOPP]]
-|style="background-color:#ff0000"|Inferior FFTF
+|style="background-color:#00cd00"|Superior FFS
 |-
-|[[Hodgkin_lymphoma#COPP-ABVD.2C_C-MOPP.2FABVD|COPP-ABVD]]
+|[[Hodgkin_lymphoma#MOPP.2FABVD|MOPP/ABVD]]
-|style="background-color:#00cd00"|Seems to have superior FFTF
+|style="background-color:#d3d3d3"|Not reported
 |-
-|[http://annonc.oxfordjournals.org/content/16/1/124.long Ballova et al. 2005 (GHSG HD9elderly)]
+|[http://jco.ascopubs.org/content/27/32/5390.long Hoskin et al. 2009 (UK NCRI ISRCTN 64141244)]
 |style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#COPP-ABVD.2C_C-MOPP.2FABVD|COPP-ABVD]]
+|[[Hodgkin_lymphoma#Stanford_V|Stanford V]]
 |style="background-color:#eeee00"|Seems not superior
 |-
-|}
+|[http://www.nejm.org/doi/full/10.1056/NEJMoa1100340 Viviani et al. 2011]
+|style="background-color:#00cd00"|Phase III
-''Note that this is technically "BEACOPP II." The original "BEACOPP I" is detailed in Diehl et al. 1997 but is of historical interest, only.''
+|[[#BEACOPP.2C_escalated_-.3E_BEACOPP|BEACOPP<sub>4+4</sub>]]
+|style="background-color:#ff0000"|Seems to have inferior FFFP
+|-
+|[http://jco.ascopubs.org/content/31/6/684.full Gordon et al. 2013 (E2496)]
+|style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#Stanford_V|Stanford V]]
+|style="background-color:#eeee00"|Seems not superior
+|-
+|[http://annonc.oxfordjournals.org/content/25/8/1622.full.html Mounier et al. 2014 (LYSA H34)]
+|style="background-color:#00cd00"|Phase III
+|[[#BEACOPP.2C_escalated_-.3E_BEACOPP|BEACOPP<sub>4+4</sub>]]
+|style="background-color:#ff0000"|Might have inferior EFS
+|-
+|[http://jco.ascopubs.org/content/34/17/2028.full Carde et al. 2016 (EORTC 20012)]
+|style="background-color:#00cd00"|Phase III
+|[[#BEACOPP.2C_escalated_-.3E_BEACOPP|BEACOPP<sub>4+4</sub>]]
+|style="background-color:#eeee00"|Seems not superior
+|-
+|}
 ====Chemotherapy====
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
+*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
+*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg) IV once on day 8
-*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
-*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
-'''3-week cycle for 8 cycles'''
+'''4-week cycle for 8 cycles'''
 ===References===
-# Diehl V, Sieber M, Rüffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol. 1997 Feb;8(2):143-8. [http://annonc.oxfordjournals.org/content/8/2/143.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9093722 PubMed]
+# Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975 Jul;36(1):252-9. [https://www.ncbi.nlm.nih.gov/pubmed/54209 PubMed]
-# Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998 Dec;16(12):3810-21. [http://jco.ascopubs.org/content/16/12/3810.long link to original article]'''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9850026 PubMed]
+# Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987 Jan;5(1):27-37. [http://jco.ascopubs.org/content/5/1/27.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2433409 PubMed]
-## '''Update:''' Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003 Jun 12;348(24):2386-95. [http://www.nejm.org/doi/full/10.1056/NEJMoa022473 link to original article]'''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12802024 PubMed]
+# Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84. [http://www.nejm.org/doi/pdf/10.1056/NEJM199211193272102 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1383821 PubMed]
-## '''Update:''' Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. [http://jco.ascopubs.org/content/27/27/4548.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19704068 PubMed]
+# Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15;21(4):607-14. [http://jco.ascopubs.org/content/21/4/607.long link to original article] [https://www.ncbi.nlm.nih.gov/12586796 PubMed]
-# Ballova V, Rüffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005 Jan;16(1):124-31. [http://annonc.oxfordjournals.org/content/16/1/124.long link to original article]'''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15598949 PubMed]
+# Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208-18. Epub 2005 Nov 28. [http://jco.ascopubs.org/content/23/36/9208.long link to original article] [https://www.ncbi.nlm.nih.gov/16314615 PubMed]
+<!-- Presented at the Annual Meeting of the American Society of Hematology, San Francisco, CA, December, 6-9, 2008; and in part at the 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, June, 7-11, 2005. -->
+# Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009 Nov 10;27(32):5390-6. Epub 2009 Sep 8. [http://jco.ascopubs.org/content/27/32/5390.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19738111 PubMed]
+# Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203-12. [http://www.nejm.org/doi/full/10.1056/NEJMoa1100340 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21774708 PubMed]
+# Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684-91. Epub 2012 Nov 26. [http://jco.ascopubs.org/content/31/6/684.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23182987 PubMed]
+## '''Subgroup analysis:''' Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013 Apr;161(1):76-86. Epub 2013 Jan 29. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906856/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23356491 PubMed]
+# Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). ABVD (8 cycles) versus BEACOPP (4 escalated cycles =4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014 Aug;25(8):1622-8. Epub 2014 May 14. [http://annonc.oxfordjournals.org/content/25/8/1622.full.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24827123 PubMed]
+# Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. J Clin Oncol. 2016 Apr 20;34(12):1376-85. Epub 2016 Feb 16. [http://jco.ascopubs.org/content/34/12/1376.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26884559 PubMed]
+# Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016 Jun 10;34(17):2020-7. Epub 2016 Apr 11. [http://jco.ascopubs.org/content/34/17/2020.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27069074 PubMed]
+# Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36. Epub 2016 Apr 25. [http://jco.ascopubs.org/content/34/17/2028.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27114593 PubMed]
+# Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. [http://www.nejm.org/doi/full/10.1056/NEJMoa1510093 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1510093/suppl_file/nejmoa1510093_protocol.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/27332902 PubMed]
-==BEACOPP-14 {{#subobject:5086b5|Regimen=1}}==
+==ABVD, DD-DI {{#subobject:fb0584|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
 |[[#top|back to top]]
 |}
-BEACOPP-14: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>14</u>'''-day course
+ABVD, DD-DI: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine, '''<u>D</u>'''ose-'''<u>D</u>'''ense and '''<u>D</u>'''ose-'''<u>I</u>'''ntense
-===Regimen {{#subobject:5e1855|Variant=1}}===
+===Regimen {{#subobject:bfb2a|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
 |[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|'''Comparator'''
-|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://jco.ascopubs.org/content/21/9/1734.full Sieber et al. 2003]
+|[http://onlinelibrary.wiley.com/doi/10.1111/bjh.12862/full Russo et al. 2014]
 |style="background-color:#eeee00"|Phase II
-|style="background-color:#d3d3d3"|
-|style="background-color:#d3d3d3"|
-|-
-|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext Engert et al. 2012 (GHSG HD15)]
-|style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_dose|Escalated BEACOPP x 8]]<br> [[Hodgkin_lymphoma#BEACOPP.2C_escalated_dose|Escalated BEACOPP x 6]]
-|
 |-
 |}
 ====Chemotherapy====
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Doxorubicin (Adriamycin)]] as follows:
-*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
+**Cycles 1 to 4: 35 mg/m<sup>2</sup> IV once per day on days 1 & 11
-*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
+**Cycles 5 & 6: 25 mg/m<sup>2</sup> IV once per day on days 1 & 11
-*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 11
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg) IV once on day 8
+*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 11
-*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
+*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once on days 1 & 11
-*[[Prednisone (Sterapred)]] 80 mg/m<sup>2</sup> PO once per day on days 1 to 7
 ====Supportive medications====
-*[[Filgrastim (Neupogen)]] as follows:
+*[[Lenograstim (Granocyte)]] 263 µg SC once per day on days 6 to 8 and days 17 to 19 (6 doses per cycle)
-**<75 kg body weight: 300 mcg SC once per day on days 8 to 13
-**≥75 kg body weight: 480 mcg SC once per day on days 8 to 13
-'''2-week cycle for 8 cycles'''
+'''21-day cycle for 6 cycles'''
 ===References===
-# Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003 May 1;21(9):1734-9. [http://jco.ascopubs.org/content/21/9/1734.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12721249 PubMed]
+# Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A. A phase II study of dose-dense and dose-intense ABVD (ABVD(DD-DI) ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. Br J Haematol. 2014 Jul;166(1):118-29. Epub 2014 Mar 27. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.12862/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24673727 PubMed]
-# Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791-9. Epub 2012 Apr 4. Erratum in: Lancet. 2012 May 12;379(9828):1790. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22480758 PubMed]
-==BEACOPP, escalated -> BEACOPP {{#subobject:d9c4c2|Regimen=1}}==
+==AVD {{#subobject:98fbb5|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
 |[[#top|back to top]]
 |}
-BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
+AVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
-===Regimen {{#subobject:5364de|Variant=1}}===
+===Regimen {{#subobject:75ea56|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
@@ Line 809: / Line 798: @@
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://www.nejm.org/doi/full/10.1056/NEJMoa1100340 Viviani et al. 2011]
+|[http://www.nejm.org/doi/full/10.1056/NEJMoa1510093 Johnson et al. 2016 (RATHL)]
 |style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#ABVD_3|ABVD]]
+|[[#ABVD_3|ABVD]]
-|style="background-color:#00cd00"|Seems to have superior FFFP
+|style="background-color:#eeee00"|Inconclusive whether non-inferior
-|-
-|[http://jco.ascopubs.org/content/29/32/4234.long Borchmann et al. 2011 (GHSG HD12)]
-|style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_dose|Escalated BEACOPP]]
-|style="background-color:#ff0000"|Inferior early progressive disease rate
-|-
-|[http://annonc.oxfordjournals.org/content/25/8/1622.full.html Mounier et al. 2014 (LYSA H34)]
-|style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#ABVD_3|ABVD]]
-|style="background-color:#00cd00"|Might have superior EFS
-|-
-|[http://jco.ascopubs.org/content/34/17/2028.full Carde et al. 2016 (EORTC 20012)]
-|style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#ABVD_3|ABVD<sub>8</sub>]]
-|style="background-color:#eeee00"|Seems not superior
 |-
 |}
-''Frequently referred to as BEACOPP<sub>escalated</sub> -> BEACOPP<sub>baseline</sub> or BEACOPP<sub>4+4</sub>.''
+''Treatment preceded by [[#ABVD_3|ABVD]] x 2.''
+====Chemotherapy====
+*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
+*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15
-====Escalated portion====
+'''4-week cycle for 4 cycles'''
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
-*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
-*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
-*[[Cyclophosphamide (Cytoxan)]] 1250 mg/m<sup>2</sup> IV once on day 1
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg per cycle) IV once on day 8
-*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
-*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
-====Supportive medications====
+===References===
-*[[Filgrastim (Neupogen)]] 300 mcg SC once per day starting day 8, continues until ANC > 1000/uL for 3 consecutive days (Viviani et al. 2011) or until day 14 (Mounier et al. 2014)
+# Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. [http://www.nejm.org/doi/full/10.1056/NEJMoa1510093 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1510093/suppl_file/nejmoa1510093_protocol.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/27332902 PubMed]
-'''3-week cycle for 4 cycles, followed by:'''
+==BEACOPP {{#subobject:2720ea|Regimen=1}}==
-====Standard portion====
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
-*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
-*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
-*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg per cycle) IV once on day 8
-*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
-*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
-====Supportive medications====
-*[[Filgrastim (Neupogen)]] 300 mcg SC once per day starting day 8, continues until ANC > 1000/uL for 3 consecutive days (Viviani et al. 2011) or until day 14 (Mounier et al. 2014)
-'''3-week cycle for 4 cycles'''
-===References===
-# Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203-12. [http://www.nejm.org/doi/full/10.1056/NEJMoa1100340 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21774708 PubMed]
-# Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. Epub 2011 Oct 11. [http://jco.ascopubs.org/content/29/32/4234.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21990399 PubMed]
-# Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). ABVD (8 cycles) versus BEACOPP (4 escalated cycles =4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014 Aug;25(8):1622-8. Epub 2014 May 14. [http://annonc.oxfordjournals.org/content/25/8/1622.full.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24827123 PubMed]
-# Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36. Epub 2016 Apr 25. [http://jco.ascopubs.org/content/34/17/2028.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27114593 PubMed]
-==BEACOPP, escalated dose {{#subobject:d6794|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
@@ Line 874: / Line 823: @@
 ===Example orders===
-*[[Example orders for escalated dose BEACOPP in Hodgkin lymphoma]]
+*[[Example orders for BEACOPP in Hodgkin lymphoma]]
-===Regimen #1 {{#subobject:c1998e|Variant=1}}===
+===Regimen {{#subobject:4e6661|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
@@ Line 883: / Line 832: @@
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext Engert et al. 2012 (GHSG HD15)]
+|[http://annonc.oxfordjournals.org/content/8/2/143.long Diehl et al. 1997]
-|style="background-color:#00cd00"|Phase III
+|style="background-color:#eeee00"|Non-randomized
-|[[Hodgkin_lymphoma#BEACOPP-14|BEACOPP-14]]<br> Escalated BEACOPP x 8
+|style="background-color:#d3d3d3"|
-|
+|style="background-color:#d3d3d3"|
 |-
-|}
+|rowspan=2|[http://jco.ascopubs.org/content/16/12/3810.long Diehl et al. 1998 (GHSG HD9)]
-''Details are not available in the abstract; it is assumed that the regimen is identical to escalated BEACOPP x 8, with 2 fewer cycles.''
+|rowspan=2 style="background-color:#00cd00"|Phase III
-====Chemotherapy====
+|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_dose|Escalated dose BEACOPP]]
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+|style="background-color:#ff0000"|Inferior FFTF
-*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
+|-
-*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
+|[[Hodgkin_lymphoma#COPP-ABVD.2C_C-MOPP.2FABVD|COPP-ABVD]]
-*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
+|style="background-color:#00cd00"|Seems to have superior OS
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg per cycle) IV once on day 8
+|-
-*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
+|[http://annonc.oxfordjournals.org/content/16/1/124.long Ballova et al. 2005 (GHSG HD9elderly)]
-*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
+|style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#COPP-ABVD.2C_C-MOPP.2FABVD|COPP-ABVD]]
-'''3-week cycle for 6 cycles'''
+|style="background-color:#eeee00"|Seems not superior
+|-
-===Regimen #2 {{#subobject:e16aa2|Variant=1}}===
+|}
-{| border="1" style="text-align:center;" !align="left"
-|'''Study'''
+''Note that this is technically "BEACOPP II." The original "BEACOPP I" is detailed in Diehl et al. 1997 but is of historical interest, only.''
-|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+====Chemotherapy====
-|'''Comparator'''
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
-|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
+*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
-|-
+*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
-|rowspan=2|[http://jco.ascopubs.org/content/16/12/3810.long Diehl et al. 1998 (GHSG HD9)]
+*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
-|rowspan=2 style="background-color:#00cd00"|Phase III
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg) IV once on day 8
-|[[Hodgkin_lymphoma#BEACOPP|BEACOPP]]
+*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
-|
+*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
-|-
-|[[Hodgkin_lymphoma#COPP-ABVD.2C_C-MOPP.2FABVD|COPP-ABVD]]
+'''3-week cycle for 8 cycles'''
-|
-|-
+===References===
-|[http://jco.ascopubs.org/content/29/32/4234.long Borchmann et al. 2011 (GHSG HD12)]
+# Diehl V, Sieber M, Rüffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol. 1997 Feb;8(2):143-8. [http://annonc.oxfordjournals.org/content/8/2/143.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9093722 PubMed]
-|style="background-color:#00cd00"|Phase III
+# Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998 Dec;16(12):3810-21. [http://jco.ascopubs.org/content/16/12/3810.long link to original article]'''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9850026 PubMed]
-|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_-.3E_BEACOPP|Escalated BEACOPP -> BEACOPP]]
+## '''Update:''' Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003 Jun 12;348(24):2386-95. [http://www.nejm.org/doi/full/10.1056/NEJMoa022473 link to original article]'''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12802024 PubMed]
-|style="background-color:#00cd00"|Superior early progressive disease rate
+## '''Update:''' Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. [http://jco.ascopubs.org/content/27/27/4548.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19704068 PubMed]
-|-
+# Ballova V, Rüffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005 Jan;16(1):124-31. [http://annonc.oxfordjournals.org/content/16/1/124.long link to original article]'''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15598949 PubMed]
-|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext Engert et al. 2012 (GHSG HD15)]
-|style="background-color:#00cd00"|Phase III
+==BEACOPP-14 {{#subobject:5086b5|Regimen=1}}==
-|[[Hodgkin_lymphoma#BEACOPP-14|BEACOPP-14]]<br> Escalated BEACOPP x 6
+{| class="wikitable" style="float:right; margin-left: 5px;"
-|
+|-
-|-
+|[[#top|back to top]]
 |}
-====Chemotherapy====
+BEACOPP-14: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>14</u>'''-day course
-*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+===Regimen {{#subobject:5e1855|Variant=1}}===
-*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
+{| border="1" style="text-align:center;" !align="left"
-*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
+|'''Study'''
-*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
-*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg per cycle) IV once on day 8
+|'''Comparator'''
-*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
-*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
+|-
+|[http://jco.ascopubs.org/content/21/9/1734.full Sieber et al. 2003]
+|style="background-color:#eeee00"|Phase II
+|style="background-color:#d3d3d3"|
+|style="background-color:#d3d3d3"|
+|-
+|rowspan=2|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext Engert et al. 2012 (GHSG HD15)]
+|rowspan=2 style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_dose|Escalated BEACOPP x 8]]
+|style="background-color:#d3d3d3"|Not reported
+|-
+|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_dose|Escalated BEACOPP x 6]]
+|style="background-color:#eeee00"|Non-inferior FFTF
+|-
+|}
+====Chemotherapy====
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
+*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg) IV once on day 8
+*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
+*[[Prednisone (Sterapred)]] 80 mg/m<sup>2</sup> PO once per day on days 1 to 7
+====Supportive medications====
+*[[Filgrastim (Neupogen)]] as follows:
+**<75 kg body weight: 300 mcg SC once per day on days 8 to 13
+**≥75 kg body weight: 480 mcg SC once per day on days 8 to 13
+'''2-week cycle for 8 cycles'''
+===References===
+# Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003 May 1;21(9):1734-9. [http://jco.ascopubs.org/content/21/9/1734.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12721249 PubMed]
+# Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791-9. Epub 2012 Apr 4. Erratum in: Lancet. 2012 May 12;379(9828):1790. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22480758 PubMed]
+==BEACOPP, escalated -> BEACOPP {{#subobject:d9c4c2|Regimen=1}}==
+{| class="wikitable" style="float:right; margin-left: 5px;"
+|-
+|[[#top|back to top]]
+|}
+BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
+===Regimen {{#subobject:5364de|Variant=1}}===
+{| border="1" style="text-align:center;" !align="left"
+|'''Study'''
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+|'''Comparator'''
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
+|-
+|[http://www.nejm.org/doi/full/10.1056/NEJMoa1100340 Viviani et al. 2011]
+|style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#ABVD_3|ABVD]]
+|style="background-color:#00cd00"|Seems to have superior FFFP
+|-
+|[http://jco.ascopubs.org/content/29/32/4234.long Borchmann et al. 2011 (GHSG HD12)]
+|style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_dose|Escalated BEACOPP]]
+|style="background-color:#ff0000"|Inferior early progressive disease rate
+|-
+|[http://annonc.oxfordjournals.org/content/25/8/1622.full.html Mounier et al. 2014 (LYSA H34)]
+|style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#ABVD_3|ABVD]]
+|style="background-color:#00cd00"|Might have superior EFS
+|-
+|[http://jco.ascopubs.org/content/34/17/2028.full Carde et al. 2016 (EORTC 20012)]
+|style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#ABVD_3|ABVD<sub>8</sub>]]
+|style="background-color:#eeee00"|Seems not superior
+|-
+|}
+''Frequently referred to as BEACOPP<sub>escalated</sub> -> BEACOPP<sub>baseline</sub> or BEACOPP<sub>4+4</sub>.''
+====Escalated portion====
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
+*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 1250 mg/m<sup>2</sup> IV once on day 1
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg per cycle) IV once on day 8
+*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
+*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
+====Supportive medications====
+*[[Filgrastim (Neupogen)]] 300 mcg SC once per day starting day 8, continues until ANC > 1000/uL for 3 consecutive days (Viviani et al. 2011) or until day 14 (Mounier et al. 2014)
+'''3-week cycle for 4 cycles, followed by:'''
+====Standard portion====
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
+*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg per cycle) IV once on day 8
+*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
+*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
+====Supportive medications====
+*[[Filgrastim (Neupogen)]] 300 mcg SC once per day starting day 8, continues until ANC > 1000/uL for 3 consecutive days (Viviani et al. 2011) or until day 14 (Mounier et al. 2014)
+'''3-week cycle for 4 cycles'''
+===References===
+# Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203-12. [http://www.nejm.org/doi/full/10.1056/NEJMoa1100340 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21774708 PubMed]
+# Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. Epub 2011 Oct 11. [http://jco.ascopubs.org/content/29/32/4234.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21990399 PubMed]
+# Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). ABVD (8 cycles) versus BEACOPP (4 escalated cycles =4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014 Aug;25(8):1622-8. Epub 2014 May 14. [http://annonc.oxfordjournals.org/content/25/8/1622.full.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24827123 PubMed]
+# Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36. Epub 2016 Apr 25. [http://jco.ascopubs.org/content/34/17/2028.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27114593 PubMed]
+==BEACOPP, escalated dose {{#subobject:d6794|Regimen=1}}==
+{| class="wikitable" style="float:right; margin-left: 5px;"
+|-
+|[[#top|back to top]]
+|}
+BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
+===Example orders===
+*[[Example orders for escalated dose BEACOPP in Hodgkin lymphoma]]
+===Regimen #1 {{#subobject:c1998e|Variant=1}}===
+{| border="1" style="text-align:center;" !align="left"
+|'''Study'''
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+|'''Comparator'''
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
+|-
+|rowspan=2|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext Engert et al. 2012 (GHSG HD15)]
+|rowspan=2 style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#BEACOPP-14|BEACOPP-14]]
+|style="background-color:#eeee00"|Non-inferior FFTF
+|-
+|Escalated BEACOPP x 8
+|style="background-color:#00cd00"|Seems to have superior OS
+|-
+|}
+''Details are not available in the abstract; it is assumed that the regimen is identical to escalated BEACOPP x 8, with 2 fewer cycles.''
+====Chemotherapy====
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
+*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg per cycle) IV once on day 8
+*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
+*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
+'''3-week cycle for 6 cycles'''
+===Regimen #2 {{#subobject:e16aa2|Variant=1}}===
+{| border="1" style="text-align:center;" !align="left"
+|'''Study'''
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+|'''Comparator'''
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
+|-
+|rowspan=2|[http://jco.ascopubs.org/content/16/12/3810.long Diehl et al. 1998 (GHSG HD9)]
+|rowspan=2 style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#BEACOPP|BEACOPP]]
+|style="background-color:#00cd00"|Superior FFTF
+|-
+|[[Hodgkin_lymphoma#COPP-ABVD.2C_C-MOPP.2FABVD|COPP-ABVD]]
+|style="background-color:#00cd00"|Seems to have superior OS
+|-
+|[http://jco.ascopubs.org/content/29/32/4234.long Borchmann et al. 2011 (GHSG HD12)]
+|style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_-.3E_BEACOPP|Escalated BEACOPP -> BEACOPP]]
+|style="background-color:#00cd00"|Superior early progressive disease rate
+|-
+|rowspan=2|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext Engert et al. 2012 (GHSG HD15)]
+|rowspan=2 style="background-color:#00cd00"|Phase III
+|[[Hodgkin_lymphoma#BEACOPP-14|BEACOPP-14]]
+|style="background-color:#d3d3d3"|Not reported
+|-
+|Escalated BEACOPP x 6
+|style="background-color:#ff0000"|Seems to have inferior OS
+|-
+|}
+====Chemotherapy====
+*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
+*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
+*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
+*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2mg per cycle) IV once on day 8
+*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
+*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
 '''3-week cycle for 8 cycles'''
@@ Line 1,024: / Line 1,152: @@
 |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 |-
-|rowspan=2|[http://jco.ascopubs.org/content/16/12/3810.long Diehl et al. 1998 (GHSG HD9)]
+|[http://jco.ascopubs.org/content/16/12/3810.long Diehl et al. 1998 (GHSG HD9)]
-|rowspan=2 style="background-color:#00cd00"|Phase III
+|style="background-color:#00cd00"|Phase III
-|[[#BEACOPP|BEACOPP]]
+|[[#BEACOPP|BEACOPP]]<br> [[Hodgkin_lymphoma#BEACOPP.2C_escalated_dose|Escalated dose BEACOPP]]
-|
+|style="background-color:#ff0000"|Seems to have inferior OS
-|-
-|[[Hodgkin_lymphoma#BEACOPP.2C_escalated_dose|Escalated dose BEACOPP]]
-|
 |-
 |[http://jjco.oxfordjournals.org/content/30/3/146.long Takenaka et al. 2000 (JCOG 8905)]
@@ Line 1,105: / Line 1,230: @@
 |style="background-color:#eeee00"|Seems not superior
 |-
-|[http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A/abstract Cooper et al. 1980]
+|rowspan=3|[http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A/abstract Cooper et al. 1980]
-|style="background-color:#00cd00"|Phase III
+|rowspan=3 style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma_-_obsolete#CVPP|CVPP]]<br> [[Hodgkin_lymphoma_-_obsolete#MVPP|MVPP]]
+|[[Hodgkin_lymphoma_-_obsolete#COPP|COPP]]
-|
+|style="background-color:#eeee00"|Seems not superior
+|-
+|[[Hodgkin_lymphoma_-_obsolete#CVPP|CVPP]]
+|style="background-color:#ff0000"|Seems to have inferior CR rate
+|-
+|[[Hodgkin_lymphoma_-_obsolete#MVPP|MVPP]]
+|style="background-color:#eeee00"|Seems not superior
 |-
 |[http://www.nejm.org/doi/full/10.1056/NEJM198204013061303 Santoro et al. 1982]
@@ Line 1,125: / Line 1,256: @@
 |style="background-color:#eeee00"|Seems not superior
 |-
-|[http://www.nejm.org/doi/full/10.1056/NEJM199211193272102 Canellos et al. 1992]
+|rowspan=2|[http://www.nejm.org/doi/full/10.1056/NEJM199211193272102 Canellos et al. 1992]
-|style="background-color:#00cd00"|Phase III
+|rowspan=2 style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#ABVD_3|ABVD]]<br> [[Hodgkin_lymphoma#MOPP.2FABVD|MOPP/ABVD]]
+|[[Hodgkin_lymphoma#ABVD_3|ABVD]]
-|
+|style="background-color:#ff0000"|Inferior FFS
+|-
+|[[Hodgkin_lymphoma#MOPP.2FABVD|MOPP/ABVD]]
+|style="background-color:#ff0000"|Seems to have inferior FFS
 |-
 |[http://jco.ascopubs.org/content/12/2/279.long Somers et al. 1994]
@@ Line 1,208: / Line 1,342: @@
 |[[#top|back to top]]
 |}
-MOPP: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
+MOPP/ABVD: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
-<br>
-ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
 ===Regimen {{#subobject:5b28f5|Variant=1}}===
@@ Line 1,224: / Line 1,356: @@
 |style="background-color:#00cd00"|Superior PFS
 |-
-|[http://www.nejm.org/doi/full/10.1056/NEJM199211193272102 Canellos et al. 1992]
+|rowspan=2|[http://www.nejm.org/doi/full/10.1056/NEJM199211193272102 Canellos et al. 1992]
-|style="background-color:#00cd00"|Phase III
+|rowspan=2 style="background-color:#00cd00"|Phase III
-|[[Hodgkin_lymphoma#ABVD_3|ABVD]]<br> [[#MOPP|MOPP]]
+|[[Hodgkin_lymphoma#ABVD_3|ABVD]]
-|
+|style="background-color:#d3d3d3"|Not reported
+|-
+|[[#MOPP|MOPP]]
+|style="background-color:#00cd00"|Seems to have superior FFS
 |-
 |[http://jco.ascopubs.org/content/12/2/279.long Somers et al. 1994]
@@ Line 1,332: / Line 1,467: @@
 ====Supportive medications====
-*If dose reduction or delay occurred at any time during chemotherapy, [[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day x 5 days (starting 48 hours after myelosuppressive chemotherapy) should be given after all subsequent day 1 and 15 doses of chemotherapy.  It was not precisely specified when to discontinue [[Filgrastim (Neupogen)]].
+*If dose reduction or delay occurred at any time during chemotherapy, [[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day x 5 days (starting 48 hours after myelosuppressive chemotherapy) should be given after all subsequent day 1 and 15 doses of chemotherapy. It was not precisely specified when to discontinue [[Filgrastim (Neupogen)]].
 *[[Ranitidine (Zantac)]] 150 mg PO BID throughout the course of treatment
 *[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] (160/800 mg) PO BID throughout the course of treatment
@@ Line 1,351: / Line 1,486: @@
 Dose reductions and delayed treatment:
-*Doses of [[Doxorubicin (Adriamycin)]], [[Vinblastine (Velban)]], [[Mechlorethamine (Mustargen)]], and [[Etoposide (Vepesid)]] were reduced to 65% of the original dose if the ANC on the day of treatment was 500 to 1000.  If ANC was <500 the day of treatment, therapy was delayed for 1 week, and therapy resumed the following week at the dose indicated by the ANC.  As noted above, [[Filgrastim (Neupogen)]] was incorporated into all subsequent treatments if there were any dose reductions or delays.
+*Doses of [[Doxorubicin (Adriamycin)]], [[Vinblastine (Velban)]], [[Mechlorethamine (Mustargen)]], and [[Etoposide (Vepesid)]] were reduced to 65% of the original dose if the ANC on the day of treatment was 500 to 1000. If ANC was <500 the day of treatment, therapy was delayed for 1 week, and therapy resumed the following week at the dose indicated by the ANC. As noted above, [[Filgrastim (Neupogen)]] was incorporated into all subsequent treatments if there were any dose reductions or delays.
 ===References===
 # Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol. 1995 May;13(5):1080-8. [http://jco.ascopubs.org/content/13/5/1080.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7537796 PubMed]
 ## '''Update:''' Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002 Feb 1;20(3):630-7. [http://jco.ascopubs.org/content/20/3/630.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11821442 PubMed]
-# Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol. 2000 Mar;18(5):972-80. [http://jco.ascopubs.org/content/18/5/972.long link to original article]  [https://www.ncbi.nlm.nih.gov/pubmed/10694546 PubMed]
+# Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol. 2000 Mar;18(5):972-80. [http://jco.ascopubs.org/content/18/5/972.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10694546 PubMed]
 <!-- Presented at the Annual Meeting of the American Society of Hematology, San Francisco, CA, December, 6-9, 2008; and in part at the 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, June, 7-11, 2005. -->
 # Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009 Nov 10;27(32):5390-6. Epub 2009 Sep 8. [http://jco.ascopubs.org/content/27/32/5390.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19738111 PubMed]
@@ Line 1,475: / Line 1,610: @@
 ===References===
 <!-- # '''Abstract:''' Christopher A. Yasenchak, MD, Robert Chen, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Beata Holkova, MD, Peter J. Rosen, MD, Jonathan W. Friedberg, MD, Megan M. O'Meara, MD and Andres Forero-Torres, MD. A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results. ASH 2013 Abstract 4389 [https://ash.confex.com/ash/2013/webprogram/Paper59615.html link to abstract]
-## '''Update: Abstract:''' Andres Forero-Torres, MD, Beata Holkova, MD, Jeff P. Sharman, MD, Jonathan W. Friedberg, MD, Maurice J. Berkowitz, MD, William Fintel, MD, Robert Chen, MD, Ralph V. Boccia, MD, Mansoor Saleh, MD, Neil Josephson, MD, Maria Corinna Palanca-Wessels, MD, PhD and Christopher A. Yasenchak, MD. Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above:  Interim Results of a Phase 2 Study. ASH 2014 Abstract 294 [https://ash.confex.com/ash/2014/webprogram/Paper68173.html link to abstract] -->
+## '''Update: Abstract:''' Andres Forero-Torres, MD, Beata Holkova, MD, Jeff P. Sharman, MD, Jonathan W. Friedberg, MD, Maurice J. Berkowitz, MD, William Fintel, MD, Robert Chen, MD, Ralph V. Boccia, MD, Mansoor Saleh, MD, Neil Josephson, MD, Maria Corinna Palanca-Wessels, MD, PhD and Christopher A. Yasenchak, MD. Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study. ASH 2014 Abstract 294 [https://ash.confex.com/ash/2014/webprogram/Paper68173.html link to abstract] -->
 # Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC, Wang Y, Yasenchak CA. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015 Dec 24;126(26):2798-804. Epub 2015 Sep 16. [http://www.bloodjournal.org/content/126/26/2798.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26377597 PubMed]
@@ Line 2,031: / Line 2,166: @@
 *[[Filgrastim (Neupogen)]] 5 mcg/kg SQ per day, start 24 hours after last dose of [[Cytarabine (Cytosar)]] and continue until ANC >2,500 for 3 days
-'''Variable number of days between cycles depending on count recovery x 2 cycles'''  Median time between cycle 1 and 2 was 16 days.  The paper did not definitively specify what criteria needed to be fulfilled before cycle 2 was given.  Baseline eligibility criteria for the study included WBC >3.5 x 10^3, Hb =8, platelets =100 x 10^3.
+'''Variable number of days between cycles depending on count recovery x 2 cycles''' Median time between cycle 1 and 2 was 16 days. The paper did not definitively specify what criteria needed to be fulfilled before cycle 2 was given. Baseline eligibility criteria for the study included WBC >3.5 x 10^3, Hb =8, platelets =100 x 10^3.
 ===References===
@@ Line 2,095: / Line 2,230: @@
 ===References===
-# Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May;85(5):320-4.  [http://onlinelibrary.wiley.com/doi/10.1002/ajh.21664/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20229590 PubMed]
+# Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May;85(5):320-4. [http://onlinelibrary.wiley.com/doi/10.1002/ajh.21664/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20229590 PubMed]
 ==GCD +/- R {{#subobject:8d6834|Regimen=1}}==
@@ Line 2,226: / Line 2,361: @@
 Dose levels:
-'''Note''': These dose levels are listed primarily for historical purposes and were used in the trial while dose levels and dose limiting toxicities (DLT) and maximum tolerated dose (MTD) were being determined.  The MTD dosages used above correspond to dose level 1 for transplant-naive patients and dose level -1 for post-transplant patients.
+'''Note''': These dose levels are listed primarily for historical purposes and were used in the trial while dose levels and dose limiting toxicities (DLT) and maximum tolerated dose (MTD) were being determined. The MTD dosages used above correspond to dose level 1 for transplant-naive patients and dose level -1 for post-transplant patients.
 *Dose level 1:
@@ Line 2,735: / Line 2,870: @@
 ====Graft-versus-host disease prophylaxis====
-*Cyclosporine A (not specified whether modified or non-modified) starting at 1.5 mg/kg BID IV on day -2
+*Cyclosporine A (not specified whether modified or non-modified) starting on day -2 at 1.5 mg/kg IV BID
 *[[Methotrexate (MTX)]] 10 mg/m<sup>2</sup> IV once per day on days +1, +3, +6, +11

Difference between revisions of "Classical Hodgkin lymphoma"

Revision as of 13:04, 26 December 2016

Untreated, early-stage favorable

ABVD

Example orders

Regimen

Chemotherapy

References

ABVD -> RT

Example orders

Regimen #1, ABVD x 2 -> IFRT

Chemotherapy

Regimen #2, ABVD x 3 -> IFRT

Chemotherapy

Regimen #3, ABVD x 3 -> INRT

Chemotherapy

Regimen #4, ABVD x 4 -> IFRT

Chemotherapy

Regimen #5, ABVD x 2 -> EFRT

Chemotherapy

Regimen #6, ABVD x 4 -> STNI

Chemotherapy

References

AVD -> IFRT

Regimen

Chemotherapy

References

MOPP-ABV -> IFRT

Regimen

Chemotherapy

References

Untreated, early-stage unfavorable

ABVD

Example orders

Regimen

Chemotherapy

References

ABVD -> RT

Example orders

Regimen

Chemotherapy

References

BEACOPP -> IFRT

Example orders

Regimen

Chemotherapy

References

BEACOPP, escalated -> ABVD -> RT

Regimen

Chemotherapy, escalated BEACOPP portion

Supportive medications

Chemotherapy, ABVD portion

References

BV + AVD -> ISRT

Regimen

Chemotherapy

References

MOPP-ABV -> IFRT

Regimen #1

Chemotherapy

Regimen #2

Chemotherapy

References

Stanford V -> RT

Regimen

Chemotherapy

References

Untreated, advanced stage

ABVD

Example orders

Regimen #1, PET-adapted

Chemotherapy

Regimen #2, 8 cycles (ABVD8)

Chemotherapy

References

ABVD, DD-DI

Regimen

Chemotherapy

Supportive medications

References

Regimen #2, 8 cycles (ABVD₈)